Integer (ITGR) 10-Q 8 Nov 16 2016 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2016	Nov. 02, 2016
Document and Entity Information [Abstract]
Entity Registrant Name	INTEGER HOLDINGS CORPORATION
Entity Central Index Key	1,114,483
Document Type	10-Q
Document Period End Date	Sep. 30, 2016
Amendment Flag	false
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--12-30
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		30,854,544

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - Unaudited - USD ($) $ in Thousands	Sep. 30, 2016	Jan. 01, 2016
Current assets:
Cash and cash equivalents	$ 44,995	$ 82,478
Accounts receivable, net of allowance for doubtful accounts of $1.1 million and $1.0 million, respectively	191,409	207,342
Inventories	262,232	252,166
Refundable income taxes	3,257	11,730
Prepaid expenses and other current assets	23,246	20,888
Total current assets	525,139	574,604
Property, plant and equipment, net	381,671	379,492
Amortizing intangible assets, net	872,659	893,977
Indefinite-lived intangible assets	90,288	90,288
Goodwill	977,335	1,013,570
Deferred income taxes	3,081	3,587
Other assets	30,794	26,618
Total assets	2,880,967	2,982,136
Current liabilities:
Current portion of long-term debt	29,000	29,000
Accounts payable	86,290	84,362
Income taxes payable	2,641	3,221
Accrued expenses	81,960	97,257
Total current liabilities	199,891	213,840
Long-term debt	1,717,164	1,685,053
Deferred income taxes	207,183	221,804
Other long-term liabilities	15,704	10,814
Total liabilities	2,139,942	2,131,511
Stockholders’ equity:
Preferred stock, $0.001 par value, authorized 100,000,000 shares; no shares issued or outstanding	0	0
Common stock, $0.001 par value; 100,000,000 shares authorized; 30,939,907 and 30,664,119 shares issued, respectively; 30,805,320 and 30,601,167 shares outstanding, respectively	31	31
Additional paid-in capital	632,409	620,470
Treasury stock, at cost, 134,587 and 62,952 shares, respectively	(5,880)	(3,100)
Retained earnings	101,154	231,854
Accumulated other comprehensive income	13,311	1,370
Total stockholders’ equity	741,025	850,625
Total liabilities and stockholders’ equity	$ 2,880,967	$ 2,982,136

Condensed Consolidated Balance3

Condensed Consolidated Balance Sheets - Unaudited (Parenthetical) - USD ($) $ in Millions	Sep. 30, 2016	Jan. 01, 2016
Current assets:
Allowance for doubtful accounts	$ 1.1	$ 1
Stockholders’ equity:
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	100,000,000	100,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	30,939,907	30,664,119
Common stock, shares outstanding	30,805,320	30,601,167
Treasury stock, shares	134,587	62,952

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations and Comprehensive Income - Unaudited - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Oct. 02, 2015	Sep. 30, 2016	Oct. 02, 2015
Income Statement [Abstract]
Sales	$ 346,567	$ 146,637	$ 1,027,187	$ 482,847
Cost of sales	248,658	94,991	741,779	320,852
Gross profit	97,909	51,646	285,408	161,995
Operating expenses:
Selling, general and administrative expenses	36,265	22,308	115,781	69,021
Research, development and engineering costs, net	11,412	14,299	42,358	39,907
Other operating expenses, net	13,370	13,844	50,004	29,449
Total operating expenses	61,047	50,451	208,143	138,377
Operating income	36,862	1,195	77,265	23,618
Interest expense, net	27,870	5,825	83,395	8,151
Other expense (income), net	275	(4,636)	(2,772)	(6,294)
Income (loss) before provision (benefit) for income taxes	8,717	6	(3,358)	21,761
Provision (benefit) for income taxes	(2,741)	(16)	(1,386)	4,448
Net income (loss)	$ 11,458	$ 22	$ (1,972)	$ 17,313
Earnings (loss) per share:
Basic	$ 0.37	$ 0	$ (0.06)	$ 0.68
Diluted	$ 0.37	$ 0	$ (0.06)	$ 0.66
Weighted average shares outstanding:
Basic	30,782	25,536	30,756	25,424
Diluted	31,153	26,441	30,756	26,372
Comprehensive Income
Net income (loss)	$ 11,458	$ 22	$ (1,972)	$ 17,313
Foreign currency translation gain (loss)	3,191	144	12,250	(1,467)
Net change in cash flow hedges, net of tax	571	689	(309)	0
Other comprehensive income (loss)	3,762	833	11,941	(1,467)
Comprehensive income	$ 15,220	$ 855	$ 9,969	$ 15,846

Condensed Consolidated Stateme5

Condensed Consolidated Statements of Cash Flows - Unaudited - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Oct. 02, 2015
Cash flows from operating activities:
Net income (loss)	$ (1,972)	$ 17,313
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Depreciation and amortization	67,414	26,941
Debt related amortization included in interest expense	5,387	5,368
Stock-based compensation	7,179	9,044
Other non-cash losses (gains), net	1,938	(1,549)
Deferred income taxes	(12,519)	(3,614)
Changes in operating assets and liabilities:
Accounts receivable	12,510	17,395
Inventories	(10,010)	(34,992)
Prepaid expenses and other current assets	(4,663)	(1,371)
Accounts payable	4,885	3,347
Accrued expenses	(5,650)	(5,823)
Income taxes	7,300	(1,074)
Net cash provided by operating activities	71,799	30,985
Cash flows from investing activities:
Acquisition of property, plant and equipment	(46,968)	(31,307)
Purchase of cost and equity method investments, net	(2,917)	(6,300)
Other investing activities	(1,000)	732
Net cash used in investing activities	(50,885)	(36,875)
Cash flows from financing activities:
Principal payments of long-term debt	(28,750)	(7,500)
Proceeds from issuance of long-term debt	57,000	0
Issuance of common stock	723	5,988
Payment of debt issuance costs	(781)	0
Distribution of cash and cash equivalents to Nuvectra Corporation	(76,256)	0
Purchase of non-controlling interests	(6,818)	0
Other financing activities	(3,983)	(318)
Net cash used in financing activities	(58,865)	(1,830)
Effect of foreign currency exchange rates on cash and cash equivalents	468	(510)
Net decrease in cash and cash equivalents	(37,483)	(8,230)
Cash and cash equivalents, beginning of period	82,478	76,824
Cash and cash equivalents, end of period	$ 44,995	$ 68,594

Condensed Consolidated Stateme6

Condensed Consolidated Statement of Stockholders' Equity - Unaudited - 9 months ended Sep. 30, 2016 - USD ($) shares in Thousands, $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Treasury Stock [Member]	Retained Earnings [Member]	Accumulated Other Comprehensive Income (Loss) [Member]
Balance, shares at Jan. 01, 2016		30,664		(63)
Balance at Jan. 01, 2016	$ 850,625	$ 31	$ 620,470	$ (3,100)	$ 231,854	$ 1,370
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Stock-based compensation	7,179		7,179
Net shares issued under stock incentive plans, shares		276		(72)
Net shares issued (acquired) under stock incentive plans	(3,261)	$ 0	(481)	$ (2,780)
Spin-off of Nuvectra Corporation	(123,487)		5,241		(128,728)
Net income (loss)	(1,972)				(1,972)
Total other comprehensive income, net	11,941					11,941
Balance, shares at Sep. 30, 2016		30,940		(135)
Balance at Sep. 30, 2016	$ 741,025	$ 31	$ 632,409	$ (5,880)	$ 101,154	$ 13,311

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2016
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation – The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information (Accounting Standards Codification (“ASC”) 270, Interim Reporting ) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these financial statements do not include all of the information necessary for a full presentation of financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. In the opinion of management, the condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the results of Integer Holdings Corporation and its subsidiaries (collectively “Integer” or the “Company”) for the periods presented. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, certain components of equity, sales, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ materially from these estimates. The January 1, 2016 condensed consolidated balance sheet data was derived from the Company’s audited consolidated financial statements but does not include all disclosures required by GAAP. For further information, refer to the consolidated financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended January 1, 2016 . The Company utilizes a fifty-two, fifty-three week fiscal year ending on the Friday nearest December 31. The third quarter and first nine months of 2016 and 2015 each contained 13 weeks and 39 weeks, respectively, and ended on September 30, and October 2, respectively. Effective June 30, 2016, the Company changed its name from Greatbatch, Inc. (“Greatbatch”) to Integer Holdings Corporation. The new name represents the union of the Greatbatch Medical, Lake Region Medical and Electrochem brands. Integer, as in whole or complete, signifies the Company’s more comprehensive products and service offerings, and a new dimension in its combined capabilities. Nature of Operations – On October 27, 2015, the Company acquired all of the outstanding common stock of Lake Region Medical Holdings, Inc. (“Lake Region Medical”). As a result, the Company has three reportable segments: Greatbatch Medical, QiG Group (“QiG”) and Lake Region Medical. On March 14, 2016, Integer completed the spin-off of a portion of its QiG segment through a tax-free distribution of all of the shares of its QiG Group, LLC subsidiary to the stockholders of Integer on a pro rata basis (the “Spin-off”). See Note 2 “Divestiture and Acquisition” for further description of these transactions. As a result of the Lake Region Medical acquisition and the Spin-off, the Company is in the process of re-evaluating its internal management and financial reporting structure, which may change its product line and segment reporting in the future. This process is expected to be finalized in 2016. Greatbatch Medical designs and manufactures products where the Company either owns the intellectual property or has unique manufacturing and assembly expertise. These products include medical devices and components for the cardiac, neuromodulation, orthopedics, portable medical, vascular and energy markets among others. The QiG segment focuses on the design and development of complete medical device systems and components for our customers. After completion of the Spin-off, the operations of QiG primarily consists of Centro de Construcción de Cardioestimuladores del Uruguay (“CCC”), which was acquired in 2014. QiG seeks to assist customers in accelerating the velocity of innovation while delivering an optimized supply chain and critical cost efficiencies. The medical devices QiG designs and develops are full product solutions that utilize the medical technology expertise and capabilities residing within Greatbatch Medical and Lake Region Medical. See Note 2 “Divestiture and Acquisition” for further description of the Spin-off and how it impacted the QiG segment. Lake Region Medical has operated as a segment of Integer since it was acquired during the fourth quarter of 2015. This segment specializes in the design, development, and manufacturing of products across the medical component and device spectrum, primarily serving the cardio, vascular and advanced surgical markets. Lake Region Medical offers fully integrated outsourced manufacturing, regulatory and engineering services, contract manufacturing, finished device assembly services, original device development, and supply chain management to its customers. The Company’s customers include large multi-national original equipment manufacturers (“OEMs”) and their affiliated subsidiaries.

Divestiture and Acquisition

Divestiture and Acquisition	9 Months Ended
	Sep. 30, 2016
Divestiture and Acquisition [Abstract]
DIVESTITURE AND ACQUISITION	DIVESTITURE AND ACQUISITION Spin-off of Nuvectra Corporation On March 14, 2016, Integer completed the spin-off of a portion of its QiG segment through a tax-free distribution of all of the shares of its QiG Group, LLC subsidiary to the stockholders of Integer on a pro rata basis. Immediately prior to completion of the Spin-off, QiG Group, LLC was converted into a corporation organized under the laws of Delaware and changed its name to Nuvectra Corporation (“Nuvectra”). On March 14, 2016, each of the Company’s stockholders of record as of the close of business on March 7, 2016 (the “Record Date”) received one share of Nuvectra common stock for every three shares of Integer common stock held as of the Record Date. Upon completion of the Spin-off, Nuvectra became an independent publicly traded company whose common stock is listed on the NASDAQ stock exchange under the symbol “NVTR.” The portion of the QiG segment spun-off consisted of QiG Group, LLC and its subsidiaries: (i) Algostim, LLC (“Algostim”), (ii) PelviStim LLC (“PelviStim”), and (iii) the Company’s NeuroNexus Technologies (“NeuroNexus”) subsidiary. The operations of CCC and certain other existing QiG research and development capabilities were retained by the Company and not included as part of the Spin-off. As the Company continues to focus on the design and development of complete medical device systems and components, and more specifically on medical device systems and components in the neuromodulation market, the Spin-off was not considered a strategic shift that had a major effect on the Company’s operations and financial results. Accordingly, the Spin-off is not presented as a discontinued operation in the Company’s Condensed Consolidated Financial Statements. The results of Nuvectra are included in the Condensed Consolidated Statements of Operations and Comprehensive Income through the date of the Spin-off. In connection with the Spin-off, during the first quarter of 2016, the Company made a cash capital contribution of $75 million to Nuvectra and divested the following assets and liabilities (in thousands): Assets divested Cash and cash equivalents $ 76,256 Other current assets 977 Property, plant and equipment, net 4,407 Amortizing intangible assets, net 1,931 Goodwill 40,830 Deferred income taxes 6,446 Total assets divested 130,847 Liabilities transferred Current liabilities 2,119 Net assets divested $ 128,728 For the first quarter of 2016, Nuvectra contributed a pre-tax loss of $5.2 million to the Company’s results of operations. Nuvectra contributed a pre-tax loss of $7.0 million and $18.7 million , respectively, to the Company’s results of operations for the three and nine month periods ended October 2, 2015. In connection with the Spin-off, on March 14, 2016, Integer entered into several agreements with Nuvectra that govern its post Spin-off relationship with Nuvectra, including a Separation and Distribution Agreement, Tax Matters Agreement, Employee Matters Agreement and Transition Services Agreement. The Transition Services Agreement contains customary mutual indemnification provisions. Amounts earned by Integer under the Transition Services Agreement were immaterial for the nine month period ended September 30, 2016. Accounts Receivable, Net within the Condensed Consolidated Balance Sheet at September 30, 2016 includes $7.0 million due from Nuvectra for payments made by the Company on Nuvectra’s behalf. Acquisition of Lake Region Medical Holdings, Inc. On October 27, 2015, the Company acquired all of the outstanding common stock of Lake Region Medical Holdings, Inc. for a total purchase price, including debt assumed, of approximately $1.77 billion . Lake Region Medical specializes in the design, development, and manufacturing of products across the medical component and device spectrum primarily serving the cardio, vascular and advanced surgical markets. 2. DIVESTITURE AND ACQUISITION (Continued) The aggregate consideration paid to the stockholders and equity award holders of Lake Region Medical consisted of the following (in thousands): Cash $ 478,490 Fair value of Integer common stock 245,368 Replacement stock options attributable to pre-acquisition service 4,508 Total purchase consideration $ 728,366 The fair value of the Integer common stock issued as part of the consideration was determined based upon the closing stock price of Integer’s shares as of the acquisition date. The fair value of the Integer stock options issued as part of the consideration was determined utilizing a Black-Scholes option pricing model as of the acquisition date. Concurrent with the closing of the acquisition, the Company repaid all of the outstanding debt of Lake Region Medical of approximately $1.0 billion . The cash portion of the purchase price and the repayment of Lake Region Medical’s debt was primarily funded through new senior secured credit facilities and the issuance of senior notes. See Note 6 “Debt” for additional information regarding the Company’s debt. The Company believes that the combination of Greatbatch and Lake Region Medical brings together two highly complementary organizations that can provide a new level of industry leading capabilities and services to OEM customers while building value for stockholders. Through this acquisition, the Company believes that it will be at the forefront of innovating technologies and products that help change the face of healthcare, providing its customers with a distinct advantage as they bring complete systems and solutions to market. In turn, Integer’s customers will be able to accelerate patient access to life enhancing therapies. The transaction is consistent with Integer's strategy of achieving profitable growth and continuous improvement to drive margin expansion. This transaction was accounted for under the acquisition method of accounting. Accordingly, the cost of the acquisition was allocated to the Lake Region Medical assets acquired and liabilities assumed based on their fair values as of the closing date of the acquisition, with the amount exceeding the fair value of the net assets acquired recorded as goodwill. Measurement-period adjustments made during the first nine months of 2016 were primarily to goodwill ( $1.1 million ) and deferred tax liabilities ( $2.6 million ), and did not impact the Company’s Condensed Consolidated Statements of Operations and Comprehensive Income. The measurement-period for this acquisition is now closed and no further purchase price adjustments will be made. The following table summarizes the allocation of the Lake Region Medical purchase price to the assets acquired and liabilities assumed (in thousands): Assets acquired Current assets $ 269,815 Property, plant and equipment 216,473 Amortizing intangible assets 849,000 Indefinite-lived intangible assets 70,000 Goodwill 660,670 Other non-current assets 1,629 Total assets acquired 2,067,587 Liabilities assumed Current liabilities 103,986 Debt assumed 1,044,675 Other long-term liabilities 190,560 Total liabilities assumed 1,339,221 Net assets acquired $ 728,366 2. DIVESTITURE AND ACQUISITION (Continued) The fair values of the assets acquired were determined using one of three valuation approaches: market, income or cost. The selection of a particular method for a given asset depended on the reliability of available data and the nature of the asset, among other considerations. The market approach estimates the value for a subject asset based on available market pricing for comparable assets. The income approach estimates the value for a subject asset based on the present value of cash flows projected to be generated by the asset. The projected cash flows were discounted at a required rate of return that reflects the relative risk of the asset and the time value of money. The projected cash flows for each asset considered multiple factors from the perspective of a marketplace participant including revenue projections from existing customers, attrition trends, technology life-cycle assumptions, marginal tax rates and expected profit margins giving consideration to historical and expected margins. The cost approach estimates the value for a subject asset based on the cost to replace the asset and reflects the estimated reproduction or replacement cost for the asset, less an allowance for loss in value due to depreciation or obsolescence, with specific consideration given to economic obsolescence if indicated. These fair value measurement approaches are based on significant unobservable inputs, including management estimates and assumptions. Current Assets and Liabilities – The fair value of current assets and liabilities, excluding inventory, was assumed to approximate their carrying value as of the acquisition date due to the short-term nature of these assets and liabilities. The fair value of in-process and finished goods inventory acquired was estimated by applying a version of the market approach called the comparable sales method. This approach estimates the fair value of the assets by calculating the potential revenue generated from selling the inventory and subtracting from it the costs related to the completion and sale of that inventory and a reasonable profit allowance. Based upon this methodology, the Company recorded the inventory acquired at fair value resulting in an increase in inventory of $23.0 million . This step-up in the fair value of inventory was amortized as the inventory to which the step-up relates was sold and was fully amortized as of January 1, 2016. Property, Plant and Equipment – The fair value of property, plant & equipment acquired was estimated by applying the cost approach for personal property, buildings and building improvements and the market approach for land. The cost approach was applied by developing a replacement cost and adjusting for depreciation and obsolescence. The value of the land acquired was derived from market prices for comparable properties. Intangible Assets – The purchase price was allocated to intangible assets as follows (dollars in thousands): Amortizing Intangible Assets Fair Value Assigned Weighted Average Amortization Period (Years) Estimated Useful Life (Years) Weighted Average Discount Rate Technology $ 160,000 7 19 11.5% Customer lists 689,000 14 29 11.5% $ 849,000 13 27 11.5% Indefinite-lived Intangible Assets Trademarks and tradenames $ 70,000 N/A N/A 11.5% The weighted average amortization period is less than the estimated useful life, as the Company is using an accelerated amortization method, which approximates the distribution of cash flows used to fair value those intangible assets. Technology – Technology consists of technical processes, patented and unpatented technology, manufacturing know-how, trade secrets and the understanding with respect to products or processes that have been developed by Lake Region Medical and that will be leveraged in current and future products. The fair value of technology acquired was determined utilizing the relief from royalty method, a form of the income approach, with a royalty rate that ranged from 0.5% to 7% . The estimated useful life of the technology is based upon management’s estimate of the product life cycle associated with the technology before it will be replaced by new technologies. 2. DIVESTITURE AND ACQUISITION (Continued) Customer Lists – Customer lists represent the estimated fair value of non-contractual customer relationships Lake Region Medical had as of the acquisition date. The primary customers of Lake Region Medical are large OEMs in various geographic locations around the world. These relationships were valued separately from goodwill at the amount that an independent third party would be willing to pay for these relationships. The fair value of customer lists was determined using the multi-period excess-earnings method, a form of the income approach. The estimated useful life of the existing customer base was based upon the historical customer annual attrition rate of 5% , as well as management’s understanding of the industry and product life cycles. Trademarks and Tradenames – Trademarks and tradenames represent the estimated fair value of Lake Region Medical’s corporate and product names. These tradenames were valued separately from goodwill at the amount that an independent third party would be willing to pay for use of these names. The fair value of the trademarks and tradenames was determined by utilizing the relief from royalty method, a form of the income approach, with a royalty rate that ranged from 0.25% to 1% . Trademarks and tradenames were assumed to have an indefinite useful life based upon the significant value the Lake Region Medical name has with OEMs in the medical component and device industries, their long history of being an industry leader and producing quality and innovative components, and given management’s current intention of using this tradename indefinitely, which was assumed to be consistent with what a reasonable market participant would also assume. Goodwill – The excess of the purchase price over the fair value of net tangible and intangible assets acquired and liabilities assumed was allocated to goodwill. Various factors contributed to the establishment of goodwill, including the value of Lake Region Medical’s highly trained assembled work force and management team, the incremental value resulting from Lake Region Medical’s capabilities and services to OEMs, enhanced synergies, and the expected revenue growth over time that is attributable to increased market penetration from future products and customers. The goodwill acquired in connection with the acquisition was allocated to the Lake Region Medical segment and is not deductible for tax purposes. Long-term Debt – The fair value of long-term debt was assumed to be equal to what was paid by Integer at the time of closing of the acquisition in order to retire the debt, including prepayment penalties and fees. Statements of Operations and Comprehensive Income The operating results of Lake Region Medical have been included in the Company’s Lake Region Medical segment from the date of acquisition. For the nine months ended September 30, 2016, Lake Region Medical added $ 607.1 million to the Company’s revenue and decreased the Company’s net loss by approximately $ 27.9 million . Unaudited Pro Forma Financial Information The following unaudited pro forma information presents the consolidated results of operations of the Company and Lake Region Medical as if that acquisition occurred as of the beginning of fiscal year 2014 (in thousands, except per share amounts): Three Months Ended Nine Months Ended October 2, 2015 October 2, 2015 Sales $ 349,561 $ 1,085,912 Net loss (9,215 ) (3,540 ) Loss per share: Basic $ (0.30 ) $ (0.12 ) Diluted $ (0.30 ) $ (0.12 ) 2. DIVESTITURE AND ACQUISITION (Continued) The unaudited pro forma financial information presents the combined operating results of Greatbatch and Lake Region Medical with the results prior to the acquisition date adjusted to include the pro forma impact of the amortization of acquired intangible assets, the adjustment to interest expense reflecting the amount borrowed in connection with the acquisition at Integer’s interest rates, and the impact of income taxes on the pro forma adjustments utilizing the applicable statutory tax rate. The unaudited pro forma consolidated basic and diluted loss per share calculations are based on the consolidated basic and diluted weighted average shares of Greatbatch outstanding for the respective period plus an adjustment for the additional shares and stock options issued in connection with the Lake Region Medical acquisition as discussed above. The unaudited pro forma financial information is presented for illustrative purposes only and does not reflect the realization of potential cost savings, and any related integration costs. Costs savings may result from the acquisition; however, there can be no assurance that these cost savings will be achieved. These pro forma results do not purport to be indicative of the results that would have been obtained by the combined company, or to be a projection of results that may be obtained in the future by the combined company.

Supplemental Cash Flow Informat

Supplemental Cash Flow Information	9 Months Ended
	Sep. 30, 2016
Supplemental Cash Flow Elements [Abstract]
SUPPLEMENTAL CASH FLOW INFORMATION	SUPPLEMENTAL CASH FLOW INFORMATION Nine Months Ended (in thousands) September 30, 2016 October 2, 2015 Noncash investing and financing activities: Property, plant and equipment purchases included in accounts payable $ 5,062 $ 892 Purchase of technology included in accrued expenses 1,000 — Common stock contributed to 401(k) Plan — 3,920 Deferred financing costs included in accounts payable — 7,922 Divestiture of noncash assets 54,591 — Divestiture of liabilities 2,119 —

Inventories

Inventories	9 Months Ended
	Sep. 30, 2016
Inventory Disclosure [Abstract]
INVENTORIES	INVENTORIES Inventories are comprised of the following (in thousands): As of September 30, 2016 January 1, 2016 Raw materials $ 114,335 $ 107,296 Work-in-process 99,892 93,729 Finished goods 48,005 51,141 Total $ 262,232 $ 252,166

Intangible Assets

Intangible Assets	9 Months Ended
	Sep. 30, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS	INTANGIBLE ASSETS Amortizing intangible assets are comprised of the following (in thousands): Gross Carrying Amount Accumulated Amortization Foreign Currency Translation Net Carrying Amount At September 30, 2016 Purchased technology and patents $ 256,719 $ (96,381 ) $ 2,750 $ 163,088 Customer lists 759,987 (55,416 ) 4,771 709,342 Other 4,534 (5,126 ) 821 229 Total amortizing intangible assets $ 1,021,240 $ (156,923 ) $ 8,342 $ 872,659 At January 1, 2016 Purchased technology and patents $ 255,776 $ (83,708 ) $ 1,444 $ 173,512 Customer lists 761,857 (40,815 ) (986 ) 720,056 Other 4,534 (4,946 ) 821 409 Total amortizing intangible assets $ 1,022,167 $ (129,469 ) $ 1,279 $ 893,977 During the first quarter of 2016, the Company made an asset purchase of technology totaling $2.0 million , which is being amortized over a weighted average period of approximately 15 years. Aggregate intangible asset amortization expense is comprised of the following (in thousands): Three Months Ended Nine Months Ended September 30, 2016 October 2, 2015 September 30, 2016 October 2, 2015 Cost of sales $ 4,228 $ 1,324 $ 12,708 $ 4,240 Selling, general and administrative expenses 5,109 1,831 15,368 5,474 Research, development and engineering costs, net 136 88 375 294 Total intangible asset amortization expense $ 9,473 $ 3,243 $ 28,451 $ 10,008 Estimated future intangible asset amortization expense based on the carrying value as of September 30, 2016 is as follows (in thousands): Estimated Amortization Expense Remainder of 2016 $ 9,478 2017 44,129 2018 45,048 2019 45,135 2020 45,734 Thereafter 683,135 Total estimated amortization expense $ 872,659 Indefinite-lived intangible assets are comprised of the following (in thousands): Trademarks and Tradenames At January 1, 2016 $ 90,288 At September 30, 2016 $ 90,288 5. INTANGIBLE ASSETS (Continued) The change in goodwill is as follows (in thousands): Greatbatch Medical QiG Lake Region Medical Total At January 1, 2016 $ 303,929 $ 50,096 $ 659,545 $ 1,013,570 Goodwill divested (Note 2) — (40,830 ) — (40,830 ) Purchase accounting adjustments (Note 2) — — (1,118 ) (1,118 ) Foreign currency translation 123 — 5,590 5,713 At September 30, 2016 $ 304,052 $ 9,266 $ 664,017 $ 977,335

Debt

Debt	9 Months Ended
	Sep. 30, 2016
Debt Disclosure [Abstract]
DEBT	DEBT Long-term debt is comprised of the following (in thousands): As of September 30, 2016 January 1, 2016 Senior secured term loan A $ 360,938 $ 375,000 Senior secured term loan B 1,017,312 1,025,000 9.125% senior notes due 2023 360,000 360,000 Revolving line of credit 50,000 — Less unamortized discount on term loan B and debt issuance costs (42,086 ) (45,947 ) Total debt 1,746,164 1,714,053 Less current portion of long-term debt 29,000 29,000 Total long-term debt $ 1,717,164 $ 1,685,053 Senior Secured Credit Facilities - In connection with the Lake Region Medical acquisition, on October 27, 2015, the Company replaced its existing credit facility with new senior secured credit facilities (the “Senior Secured Credit Facilities”) consisting of (i) a $200 million revolving credit facility (the “Revolving Credit Facility”), (ii) a $375 million term loan A facility (the “TLA Facility”), and (iii) a $1,025 million term loan B facility (the “TLB Facility”). The TLA Facility and TLB Facility are collectively referred to as the “Term Loan Facilities.” The TLB facility was issued at a 1% discount. Term Loan Facilities The TLA Facility and TLB Facility mature on October 27, 2021 and October 27, 2022 , respectively. Interest rates on the TLA Facility, as well as the Revolving Credit Facility, are at the Company’s option, either at: (i) the prime rate plus the applicable margin, which will range between 0.75% and 2.25% , based on the Company’s Total Net Leverage Ratio, as defined in the Senior Secured Credit Facilities agreement or (ii) the applicable LIBOR rate plus the applicable margin, which will range between 1.75% and 3.25% , based on the Company’s Total Net Leverage Ratio. Interest rates on the TLB Facility are, at the Company’s option, either at: (i) the prime rate plus 3.25% or (ii) the applicable LIBOR rate plus 4.25% , with LIBOR subject to a 1.00% floor. Subject to certain conditions, one or more incremental term loan facilities may be added to the Term Loan Facilities so long as, on a pro forma basis, the Company’s first lien net leverage ratio does not exceed 4.25 :1.00. As of September 30, 2016 , the estimated fair value of the TLB Facility was approximately $1,005 million , based on quoted market prices for the debt, recent sales prices for the debt and consideration of comparable debt instruments with similar interest rates and trading frequency, among other factors, and is classified as Level 2 measurements within the fair value hierarchy. The par amount of the TLA Facility approximated its fair value as of September 30, 2016 based upon the debt being variable rate in nature. 6. DEBT (Continued) Revolving Credit Facility The Revolving Credit Facility matures on October 27, 2020 . The Revolving Credit Facility also includes a $15 million sublimit for swingline loans and a $25 million sublimit for standby letters of credit. The Company is required to pay a commitment fee on the unused portion of the Revolving Credit Facility, which will range between 0.175% and 0.25% , depending on the Company’s Total Net Leverage Ratio. As of September 30, 2016 , the Company had $50 million of outstanding borrowings on the Revolving Credit Facility and an available borrowing capacity of $141.1 million after giving effect to $8.9 million of outstanding standby letters of credit. Subject to certain conditions, commitments under the Revolving Credit Facility may be increased through an incremental revolving facility so long as, on a pro forma basis, the Company’s first lien net leverage ratio does not exceed 4.25 :1.00. Covenants The Revolving Credit Facility and TLA Facility contain covenants requiring (A) a maximum Total Net Leverage Ratio of 6.50 :1.00, subject to step downs beginning in the fourth quarter of 2016 and (B) a minimum interest coverage ratio of adjusted EBITDA (as defined in the agreements governing the Senior Secured Credit Facilities) to interest expense of not less than 3.00 :1.00. The TLB Facility does not contain any financial maintenance covenants. As of September 30, 2016 , the Company was in compliance with these financial covenants. Based upon the Company’s current expectations for its 2016 adjusted EBITDA, there is a potential that it will not be able to meet its minimum interest coverage ratio at year-end 2016. The Company is working with the administrative agent under its Senior Secured Credit Facilities to obtain an amendment or waiver of the financial covenants before year-end. The Senior Secured Credit Facilities also contain negative covenants that restrict the Company’s ability to (i) incur additional indebtedness; (ii) create certain liens; (iii) consolidate or merge; (iv) sell assets, including capital stock of the Company’s subsidiaries; (v) engage in transactions with the Company’s affiliates; (vi) create restrictions on the payment of dividends or other amounts from the Company’s restricted subsidiaries; (vii) pay dividends on capital stock or redeem, repurchase or retire capital stock; (viii) pay, prepay, repurchase or retire certain subordinated indebtedness; (ix) make investments, loans, advances and acquisitions; (x) make certain amendments or modifications to the organizational documents of the Company or its subsidiaries or the documentation governing other senior indebtedness of the Company; and (xi) change the Company’s type of business. These negative covenants are subject to a number of limitations and exceptions that are described in the Senior Secured Credit Facilities agreement. As of September 30, 2016 , the Company was in compliance with all negative covenants under the Senior Secured Credit Facilities. The Senior Secured Credit Facilities provide for customary events of default. Upon the occurrence and during the continuance of an event of default, the outstanding advances and all other obligations under the Senior Secured Credit Facilities become immediately due and payable. The Senior Secured Credit Facilities are guaranteed by Integer Holdings Corporation, as a parent guarantor, and all of the Company’s present and future direct and indirect wholly-owned domestic subsidiaries (other than Greatbatch Ltd. (which is the borrower under the Senior Secured Credit Facilities), non-wholly owned joint ventures, and certain other excluded subsidiaries). The Senior Secured Credit Facilities are secured, subject to certain exceptions, by a first priority security interest in; i) the present and future shares of capital stock of (or other ownership or profit interests in) Greatbatch Ltd. and each guarantor (except Integer Holdings Corporation); ii) sixty-six percent ( 66% ) of all present and future shares of voting capital stock of each specified first-tier foreign subsidiary; iii) substantially all of the Company’s, Greatbatch Ltd.’s and each other guarantor’s other personal property; and iv) all proceeds and products of the property and assets of the Company, Greatbatch Ltd. and the other guarantors. 9.125% Senior Notes due 2023 - On October 27, 2015, the Company completed a private offering of $360 million aggregate principal amount of 9.125% senior notes due on November 1, 2023 (the “Senior Notes”). 6. DEBT (Continued) Interest on the Senior Notes is payable on May 1 and November 1 of each year. The Company may redeem the Senior Notes, in whole or in part, prior to November 1, 2018 at a price equal to 100% of the principal amount thereof plus a “make-whole” premium. Prior to November 1, 2018, the Company may redeem up to 40% of the aggregate principal amount of the Senior Notes using the proceeds from certain equity offerings at a redemption price equal to 109.125% of the aggregate principal amount of the Senior Notes. On or after November 1, 2018, the Company may redeem the Senior Notes, in whole or in part, pursuant to a customary schedule of declining redemption prices. As of September 30, 2016 , the estimated fair value of the Senior Notes was approximately $351 million , based on quoted market prices of these Senior Notes, recent sales prices for the Senior Notes and consideration of comparable debt instruments with similar interest rates and trading frequency, among other factors, and is classified as Level 2 measurements within the fair value hierarchy. The Senior Notes are senior unsecured obligations of the Company. The indenture for the Senior Notes contains restrictive covenants that, among other things, limit the ability of the Company to: (i) incur or guarantee additional indebtedness or issue certain disqualified stock or preferred stock; (ii) create certain liens; (iii) pay dividends or make distributions in respect of capital stock; (iv) make certain other restricted payments; (v) enter into agreements that restrict certain dividends or other payments; (vi) enter into sale-leaseback agreements; (vii) engage in certain transactions with affiliates; and (viii) consolidate or merge with, or sell substantially all of their assets to, another person. These covenants are subject to a number of limitations and exceptions that are described in the indenture for the Senior Notes. The indenture for the Senior Notes provides for customary events of default, subject in certain cases to customary cure periods, in which the Senior Notes and any unpaid interest would become due and payable. As of September 30, 2016 , the Company was in compliance with all restrictive covenants under the indenture governing the Senior Notes. As of September 30, 2016 , the weighted average interest rate on all outstanding borrowings is 5.69% . Contractual maturities under the Senior Secured Credit Facilities and Senior Notes for the remainder of 2016 and the five years and thereafter, excluding any discounts or premiums, as of September 30, 2016 are as follows (in thousands): Remaining in 2016 $ 7,250 2017 31,344 2018 40,719 2019 47,750 2020 97,750 Thereafter 1,563,437 Total $ 1,788,250 Interest Rate Swaps – From time to time, the Company enters into interest rate swap agreements in order to hedge against potential changes in cash flows on its outstanding variable rate debt. In July 2016, the Company entered into a one -year $250 million interest rate swap with an effective date of July 27, 2016. The Company entered into the swap to hedge against potential changes in cash flows on the outstanding variable rate debt, which is indexed to the one-month LIBOR rate. The variable rate received on the interest rate swap and the variable rate paid on the outstanding debt will have the same rate of interest, excluding the credit spread, and will reset and pay interest on the same day. The swap is being accounted for as a cash flow hedge. In June 2016, the Company entered into a three -year $200 million interest rate swap with an effective date of June 27, 2017. The Company entered into the swap to hedge against potential changes in cash flows on the outstanding variable rate debt, which is indexed to the one-month LIBOR rate. The variable rate received on the interest rate swap and the variable rate paid on the outstanding debt will have the same rate of interest, excluding the credit spread, and will reset and pay interest on the same date. The swap is being accounted for as a cash flow hedge. 6. DEBT (Continued) During 2012, the Company entered into a three -year $150 million interest rate swap, which amortized $50 million per year. During 2014, the Company entered into an additional interest rate swap. The first $45 million of notional amount of the swap was effective February 20, 2015 and the second $45 million of notional amount was scheduled to be effective February 22, 2016. These swaps were accounted for as cash flow hedges. As a result of the Lake Region Medical acquisition, the forecasted cash flows that the Company’s interest rate swaps were hedging were no longer expected to occur. During the fourth quarter of 2015, the Company terminated these interest rate swap agreements. Information regarding the Company’s outstanding interest rate swaps designated as cash flow hedges as of September 30, 2016 is as follows (dollars in thousands): Notional Amount Start Date End Date Pay Fixed Rate Receive Current Floating Rate Fair Value Balance Sheet Location $ 200,000 Jun-17 Jun-20 1.1325 % N/A $ (974 ) Other Long-Term Liabilities $ 250,000 Jul-16 Jun-17 0.615 % 0.53 % $ 75 Prepaid Expenses and Other Current Assets The estimated fair value of the interest rate swap agreements represents the amount the Company expects to receive (pay) to terminate the contract. No portion of the change in fair value of the Company’s interest rate swaps during the nine months ended September 30, 2016 and October 2, 2015 was considered ineffective. The amount recorded as Interest Expense during the nine months ended September 30, 2016 and October 2, 2015 related to the Company’s interest rate swaps was $0.05 million and $3.5 million , respectively. Debt Issuance Costs and Discounts – The change in deferred debt issuance costs related to the Revolving Credit Facility is as follows (in thousands): At January 1, 2016 $ 4,791 Amortization during the period (745 ) At September 30, 2016 $ 4,046 The change in unamortized discount and debt issuance costs related to the Term Loan Facilities and Senior Notes is as follows (in thousands): Debt Issuance Costs Unamortized Discount on TLB Facility Total At January 1, 2016 $ 35,908 $ 10,039 $ 45,947 Financing costs incurred 781 — 781 Amortization during the period (3,669 ) (973 ) (4,642 ) At September 30, 2016 $ 33,020 $ 9,066 $ 42,086

Benefit Plans

Benefit Plans	9 Months Ended
	Sep. 30, 2016
Defined Benefit Pension Plans and Defined Benefit Postretirement Plans Disclosure [Abstract]
BENEFIT PLANS	BENEFIT PLANS The Company is required to provide its employees located in Switzerland, Mexico, France, and Germany certain statutorily mandated defined benefits. Under these plans, benefits accrue to employees based upon years of service, position, age and compensation. The defined benefit pension plan provided to the Company’s employees located in Switzerland is a funded contributory plan, while the plans that provide benefits to the Company’s employees located in Mexico, France, and Germany are unfunded and noncontributory. The liability and corresponding expense related to these benefit plans is based on actuarial computations of current and future benefits for employees. The change in net defined benefit plan liability is as follows (in thousands): At January 1, 2016 $ 7,121 Net defined benefit cost 584 Benefit payments (76 ) Foreign currency translation 125 At September 30, 2016 $ 7,754 Net defined benefit cost is comprised of the following (in thousands): Three Months Ended Nine Months Ended September 30, 2016 October 2, 2015 September 30, 2016 October 2, 2015 Service cost $ 108 $ 76 $ 326 $ 233 Interest cost 44 15 132 45 Amortization of net loss 47 13 140 39 Expected return on plan assets (5 ) (2 ) (14 ) (8 ) Net defined benefit cost $ 194 $ 102 $ 584 $ 309

Stock-Based Compensation

Stock-Based Compensation	9 Months Ended
	Sep. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
STOCK-BASED COMPENSATION	STOCK-BASED COMPENSATION At the 2016 Annual Meeting of Stockholders held on May 24, 2016, the Company’s stockholders approved the Company’s 2016 Stock Incentive Plan (the “2016 Plan”). The 2016 Plan provides for the granting of stock options, shares of restricted stock, restricted stock units, stock appreciation rights and stock bonuses to employees, non-employee directors, consultants, and service providers. The 2016 Plan supplements the Company’s existing 2009 and 2011 Stock Incentive Plans, as amended. In connection with the Spin-off, under the provisions of the Company’s existing 2009 and 2011 stock incentive plans, employee stock options, restricted stock awards, and restricted stock unit awards were adjusted to preserve the fair value of the awards immediately before and after the Spin-off. As such, the Company did not record any modification expense related to the conversion of the awards. Certain awards granted to employees who transferred to Nuvectra in connection with the Spin-off were canceled. As required, the Company accelerated the remaining expense related to these canceled awards of $0.5 million during the first quarter of 2016, which was classified as Other Operating Expenses, Net. The stock awards held as of March 14, 2016 were modified as follows: • Stock options : Holders of the Company’s stock option awards continued to hold stock options to purchase the same number of shares of Integer common stock at an adjusted exercise price and one new Nuvectra stock option for every three Integer stock options held as of the Record Date, which, in the aggregate, preserved the fair value of the overall awards granted. The adjusted exercise price for Integer stock options was equal to approximately 93% of the original exercise price. The stock option awards will continue to vest over their original vesting period. • Restricted stock and restricted stock units : Holders of the Company’s restricted stock and restricted stock unit awards received one new share of Nuvectra restricted stock and restricted stock unit awards for every three Integer restricted stock and restricted stock unit awards held as of the Record Date. Integer restricted stock and restricted stock unit awards will continue to vest in accordance with their original performance metrics and over their original vesting period. The components and classification of stock-based compensation expense were as follows (in thousands): Three Months Ended Nine Months Ended September 30, 2016 October 2, 2015 September 30, 2016 October 2, 2015 Stock options $ 663 $ 697 $ 1,857 $ 1,979 Restricted stock and restricted stock units 1,554 1,701 5,322 5,081 401(k) Plan stock contribution — 674 — 1,984 Total stock-based compensation expense $ 2,217 $ 3,072 $ 7,179 $ 9,044 Cost of sales $ 158 $ 685 $ 505 $ 2,039 Selling, general and administrative expenses 1,677 1,981 4,860 5,890 Research, development and engineering costs, net 115 361 408 1,070 Other operating expenses, net 267 45 1,406 45 Total stock-based compensation expense $ 2,217 $ 3,072 $ 7,179 $ 9,044 The weighted average fair value and assumptions used to value options granted are as follows: Nine Months Ended September 30, 2016 October 2, 2015 Weighted average fair value $ 9.25 $ 12.18 Risk-free interest rate 1.56 % 1.55 % Expected volatility 26 % 26 % Expected life (in years) 5 5 Expected dividend yield — % — % 8. STOCK-BASED COMPENSATION (Continued) The following table summarizes the Company’s stock option activity: Number of Stock Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life (In Years) Aggregate Intrinsic Value (In Millions) Outstanding at January 1, 2016 1,678,900 $ 28.32 Granted 245,439 49.58 Exercised (32,833 ) 22.00 Forfeited or expired (91,385 ) 46.13 Adjustment due to Spin-off — (2.02 ) Outstanding at September 30, 2016 1,800,121 $ 28.41 5.8 $ 2.3 Exercisable at September 30, 2016 1,432,312 $ 23.87 5.0 $ 2.3 The following table summarizes time-vested restricted stock and restricted stock unit activity: Time-Vested Activity Weighted Average Fair Value Nonvested at January 1, 2016 39,235 $ 47.40 Granted 48,702 50.15 Vested (15,391 ) 51.39 Forfeited (10,835 ) 48.67 Nonvested at September 30, 2016 61,711 $ 48.35 The following table summarizes performance-vested restricted stock unit activity: Performance- Vested Activity Weighted Average Fair Value Nonvested at January 1, 2016 577,825 $ 25.11 Granted 163,651 31.20 Vested (249,153 ) 15.86 Forfeited (119,005 ) 32.15 Nonvested at September 30, 2016 373,318 $ 31.70

Other Operating Expenses, Net

Other Operating Expenses, Net	9 Months Ended
	Sep. 30, 2016
Other Income and Expenses [Abstract]
OTHER OPERATING EXPENSES, NET	OTHER OPERATING EXPENSES, NET Other Operating Expenses, Net is comprised of the following (in thousands): Three Months Ended Nine Months Ended September 30, 2016 October 2, 2015 September 30, 2016 October 2, 2015 2014 investments in capacity and capabilities $ 4,542 $ 5,116 $ 13,821 $ 17,854 Orthopedic facilities optimization 329 357 628 1,348 Lake Region Medical consolidations 2,908 — 7,355 — Acquisition and integration costs 5,319 5,202 23,143 5,366 Asset dispositions, severance and other 272 3,169 5,057 4,881 $ 13,370 $ 13,844 $ 50,004 $ 29,449 2014 investments in capacity and capabilities. In 2014, the Company announced several initiatives to invest in capacity and capabilities and to better align its resources to meet its customers’ needs and drive organic growth and profitability. These included the following: • Functions performed at the Company’s facility in Plymouth, MN to manufacture catheters and introducers will transfer into the Company’s existing facility in Tijuana, Mexico. This initiative is expected to be substantially completed in the first half of 2017 and is dependent upon our customers’ validation and qualification of the transferred products as well as regulatory approvals worldwide. • Functions performed at the Company’s facilities in Beaverton, OR and Raynham, MA to manufacture products for the portable medical market were transferred to a new facility in Tijuana, Mexico. Products manufactured at the Beaverton facility, which do not serve the portable medical market, were transferred to the Company’s Raynham facility. This initiative was substantially completed during the first half of 2016. The final closure of the Beaverton, OR site will occur in the fourth quarter of 2016. • The design engineering responsibilities previously performed at the Company’s Cleveland, OH facility were transferred to the Company’s facilities in Minnesota in 2015. • The realignment of the Company’s commercial sales operations was completed in 2015. The total capital investment expected for these initiatives is between $ 25.0 million and $ 28.0 million , of which $23.2 million has been expended through September 30, 2016 . Total restructuring charges expected to be incurred in connection with this realignment are between $ 46.0 million and $ 52.0 million , of which $ 45.8 million has been incurred through September 30, 2016 . Expenses related to this initiative are recorded within the applicable segment and corporate cost centers that the expenditures relate to and include the following: • Severance and retention: $ 5.0 million - $ 6.0 million ; • Accelerated depreciation and asset write-offs: $ 2.0 million - $3.0 million ; and • Other: $ 39.0 million - $ 43.0 million Other expenses primarily consist of costs to relocate certain equipment and personnel, duplicate personnel costs, excess overhead, disposal, and travel expenditures. All expenses are cash expenditures except accelerated depreciation and asset write-offs. The change in accrued liabilities related to the 2014 investments in capacity and capabilities is as follows (in thousands): Severance and Retention Accelerated Depreciation/Asset Write-offs Other Total At January 1, 2016 $ 1,429 $ — $ 1,595 $ 3,024 Restructuring charges — 1,787 12,034 13,821 Write-offs — (1,787 ) — (1,787 ) Cash payments (1,246 ) — (13,629 ) (14,875 ) At September 30, 2016 $ 183 $ — $ — $ 183 9. OTHER OPERATING EXPENSES, NET (Continued) Orthopedic facilities optimization. In 2010, the Company began updating its Indianapolis, IN facility to streamline operations, consolidate two buildings, increase capacity, further expand capabilities, and reduce dependence on outside suppliers. This initiative was completed in 2011. In 2011, the Company began construction of an orthopedic manufacturing facility in Fort Wayne, IN and transferred manufacturing operations being performed at its Columbia City, IN location into this new facility. This initiative was completed in 2012. In 2012, the Company transferred manufacturing and development operations performed at its facilities in Orvin and Corgemont, Switzerland into existing facilities in Fort Wayne, IN and Tijuana, Mexico. This initiative was completed in 2013. During 2013, the Company began a project to expand its Chaumont, France facility in order to enhance its capabilities and fulfill larger volume customer supply agreements. This initiative is expected to be completed over the next year. The total capital investment expected to be incurred for these initiatives is between $31.0 million and $35.0 million , of which $30.0 million has been expended through September 30, 2016 . Total expense expected to be incurred for these initiatives is between $45.0 million and $48.0 million , of which $44.5 million has been incurred through September 30, 2016 . All expenses have been and will be recorded within the Greatbatch Medical segment and are expected to include the following: • Severance and retention: approximately $11.0 million ; • Accelerated depreciation and asset write-offs: approximately $13.0 million ; and • Other: $21.0 million – $24.0 million Other expenses include production inefficiencies, moving, revalidation, personnel, training, consulting, and travel costs associated with these consolidation projects. All expenses are cash expenditures except accelerated depreciation and asset write-offs. The change in accrued liabilities related to the orthopedic facilities optimization is as follows (in thousands): Severance and Retention Accelerated Depreciation/Asset Write-offs Other Total At January 1, 2016 $ — $ — $ — $ — Restructuring charges — 202 426 628 Write-offs — (202 ) — (202 ) Cash payments — (426 ) (426 ) At September 30, 2016 $ — $ — $ — $ — Lake Region Medical consolidations. In 2014, Lake Region Medical initiated plans to close its Arvada, CO site, consolidate its two Galway, Ireland sites into one facility, and other restructuring actions that will result in a reduction in staff across manufacturing and administrative functions at certain locations. This initiative is expected to be substantially completed by the end of 2016. During the third quarter of 2016, the Company announced the planned closure of its Clarence, NY facility. The machined component product lines manufactured in this facility will be transferred to other Integer locations in the U.S. The project is expected to be completed by the first quarter of 2018. The total capital investment expected to be incurred for these initiatives is between $5.0 million and $6.0 million , of which $1.7 million has been expended through September 30, 2016 . Total expense expected to be incurred for these initiatives are between $20.0 million and $25.0 million , of which $9.3 million has been incurred through September 30, 2016 . All expenses related to these initiatives have been and will be recorded within the applicable segment and corporate cost centers that the expenditures relate to and are expected to include the following: • Employee costs: $8.0 million - $10.0 million ; • Accelerated depreciation and asset write-offs: approximately $1.0 million - $2.0 million ; and • Other: $11.0 million - $13.0 million . 9. OTHER OPERATING EXPENSES, NET (Continued) Other expenses primarily consist of production inefficiencies, moving, revalidation, personnel, training, consulting, and travel costs associated with these consolidation projects. All expenses are cash expenditures. The change in accrued liabilities related to the Lake Region Medical consolidation initiatives is as follows (in thousands): Employee Costs Accelerated Depreciation/Asset Write-offs Other Total At January 1, 2016 $ 3,667 $ — $ 596 $ 4,263 Restructuring charges 4,646 907 1,802 7,355 Write-offs — (907 ) — (907 ) Cash payments (7,392 ) — (1,942 ) (9,334 ) At September 30, 2016 $ 921 $ — $ 456 $ 1,377 Acquisition and integration costs. During the third quarter and first nine months of 2016, the Company incurred $0.2 million and $4.2 million , respectively, in transaction costs related to the acquisition of Lake Region Medical. During the third quarter of 2015, the Company incurred $5.1 million of such costs. Transaction costs primarily relate to change-in-control payments to former Lake Region Medical executives, as well as professional and consulting fees. Additionally, during the third quarter and first nine months of 2016, the Company incurred $5.2 million and $18.9 million , respectively, in Lake Region Medical integration costs, which primarily included professional, consulting, severance, retention, relocation, and travel costs. As of September 30, 2016 , $5.8 million of acquisition and integration costs related to the Lake Region Medical acquisition are accrued. Total expense expected to be incurred in connection with the integration of Lake Region Medical is between $40.0 million and $50.0 million , of which $31.7 million were incurred through September 30, 2016 . Total capital expenditures for this initiative are expected to be between $20.0 million and $25.0 million , the incurrence of which have not been material to date. Expenses related to this initiative were recorded to corporate unallocated expenses, the Greatbatch Medical segment and the Lake Region Medical segment. Asset dispositions, severance and other . During 2016 and 2015, the Company recorded losses in connection with various asset disposals and/or write-downs. In addition, during the first nine months of 2016 and 2015, the Company incurred legal and professional costs in connection with the Spin-off of $4.4 million ( $0.02 million in the third quarter of 2016) and $4.6 million ( $3.1 million in the third quarter of 2015), respectively. Total transaction related costs incurred for the Spin-off since inception were $10.4 million . Expenses related to the Spin-off were primarily recorded within the corporate unallocated and the QiG segment. Refer to Note 2 “Divestiture and Acquisition” for additional information on the Spin-off.

Income Taxes

Income Taxes	9 Months Ended
	Sep. 30, 2016
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES The income tax provision for interim periods is determined using an estimate of the annual effective tax rate, adjusted for discrete items, if any, that are taken into account in the relevant period. Each quarter, the estimate of the annual effective tax rate is updated, and if the estimated effective tax rate changes, a cumulative adjustment is made. There is a potential for volatility of the effective tax rate due to several factors, including discrete items, changes in the mix of the pre-tax income and the jurisdictions to which it relates, changes in tax laws and foreign tax holidays, business reorganizations, settlements with taxing authorities and foreign currency fluctuations. The effective tax rate for the first nine months of 2016 and 2015 was 41.3% and 20.4% , respectively. The effective tax rate for the first nine months of 2016 includes the impact of a $1.6 million ( $2.9 million for the third quarter of 2016) of net discrete tax benefits related to Lake Region Medical and Spin-off transaction costs. For fiscal year 2016, the effective tax rate is expected to be approximately (30%). The tax benefit for the third quarter and expected tax benefit for full year 2016 is due to these discrete tax items, as well as Company having projected losses in higher tax rate jurisdictions and income in lower tax rate jurisdictions. As of September 30, 2016 , the balance of unrecognized tax benefits is approximately $9.8 million . It is reasonably possible that a reduction of up to $0.1 million of the balance of unrecognized tax benefits may occur within the next twelve months as a result of potential audit settlements. Approximately $9.0 million of the balance of unrecognized tax benefits would favorably impact the effective tax rate, net of federal benefit on state issues, if recognized.

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Sep. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
COMMITMENTS AND CONTINGENCIES	COMMITMENTS AND CONTINGENCIES Litigation – In April 2013, the Company commenced an action against AVX Corporation and AVX Filters Corporation (collectively “AVX”) alleging that AVX had infringed on the Company’s patents by manufacturing and selling filtered feedthrough assemblies used in implantable pacemakers and cardioverter defibrillators that incorporate the Company’s patented technology. On January 26, 2016, a jury in the U.S. District Court for the District of Delaware returned a verdict finding that AVX infringed on two Integer patents and awarded Integer $37.5 million in damages. The finding is subject to post-trial proceedings, including a possible appeal by AVX. The Company has recorded no gains in connection with this litigation as no cash has been received. The Company is a party to various other legal actions arising in the normal course of business. The Company does not expect that the ultimate resolution of any other pending legal actions will have a material effect on its consolidated results of operations, financial position, or cash flows. However, litigation is subject to inherent uncertainties. As such, there can be no assurance that any pending legal action, which the Company currently believes to be immaterial, will not become material in the future. Environmental Matters – The Company’s Collegeville, PA facility, which was acquired as part of the Lake Region Medical acquisition, is subject to two administrative consent orders entered into with the U.S. Environmental Protection Agency (the “EPA”), which require ongoing groundwater treatment and monitoring at the site as a result of historic leaks from underground storage tanks. Upon approval by the EPA of the Company’s proposed post remediation care plan, which requires a continuation of the groundwater treatment and monitoring process at the site, the Company expects that the consent orders will be terminated. The Company expects a decision from the EPA on whether the Company’s post remediation care plan has been approved during the fourth quarter of 2016 or early 2017. The groundwater treatment process at the Collegeville facility consists of a groundwater extraction and treatment system and the performance of annual sampling of a defined set of groundwater wells as a means to monitor containment within approved boundaries. The Company does not expect this environmental matter will have a material effect on its condensed consolidated results of operations, financial position or cash flows. 11. COMMITMENTS AND CONTINGENCIES (Continued) In January 2015, Lake Region Medical was notified by the New Jersey Department of Environmental Protection (“NJDEP”) of the NJDEP’s intent to revoke a no further action determination made by the NJDEP in favor of Lake Region Medical in 2002 pertaining to a property on which a subsidiary of Lake Region Medical operated a manufacturing facility in South Plainfield, New Jersey beginning in 1971. Lake Region Medical sold the property in 2004 and vacated the facility in 2007. In response to the NJDEP’s notice, the Company further investigated the matter and submitted a technical report to the NJDEP in August of 2015 that concluded that the NJDEP’s notice of intent to revoke was unwarranted. After reviewing the Company’s technical report, the NJDEP issued a draft response in May 2016, stating that the NJDEP would not revoke the no further action determination at that time, but would require some additional site investigation to support the Company’s conclusion. The Company is cooperating with the NJDEP and has met with NJDEP representatives to discuss the appropriate scope of the requested additional investigation. The Company does not expect this environmental matter will have a material effect on its condensed consolidated results of operations, financial position or cash flows. As of September 30, 2016 and January 1, 2016, there was $1.1 million recorded in Other Long-Term Liabilities in the Condensed Consolidated Balance Sheets in connection with these environmental matters. Product Warranties – The Company generally warrants that its products will meet customer specifications and will be free from defects in materials and workmanship. The Company does not expect future product warranty claims will have a material effect on its condensed consolidated results of operations, financial position, or cash flows. However, there can be no assurance that any future customer complaints or negative regulatory actions regarding the Company’s products, which the Company currently believes to be immaterial, does not become material in the future. The change in product warranty liability was comprised of the following (in thousands): At January 1, 2016 $ 3,316 Additions to warranty reserve 1,568 Warranty claims settled (2,351 ) At September 30, 2016 $ 2,533 Foreign Currency Contracts – From time to time, the Company enters into forward contracts to purchase Mexican pesos in order to hedge the risk of peso-denominated payments associated with operations at its facilities in Mexico . In connection with the Lake Region Medical acquisition, the Company terminated its outstanding forward contracts resulting in a $2.4 million payment to the foreign currency contract counter-party during the fourth quarter of 2015. As of September 30, 2016, the Company had a $0.3 million loss recorded in Accumulated Other Comprehensive Income related to these contracts, which will be amortized to Cost of Sales as the inventory, which the contracts were hedging the cash flows to produce, is sold. The impact to the Company’s results of operations from its forward contract hedges is as follows (in thousands): Three Months Ended Nine Months Ended September 30, 2016 October 2, 2015 September 30, 2016 October 2, 2015 Addition in cost of sales $ 929 $ 562 $ 2,316 $ 1,226 Ineffective portion of change in fair value — — — — Information regarding outstanding foreign currency contracts designated as cash flow hedges as of September 30, 2016 is as follows (dollars in thousands): Aggregate Notional Amount Start Date End Date $/Peso Fair Value Balance Sheet Location $ 4,120 Jan 2016 Dec 2016 0.0584 $ (506 ) Accrued Expenses 2,795 Apr 2016 Dec 2016 0.0565 (258 ) Accrued Expenses 18,490 Jan 2017 Sep 2017 0.0514 (415 ) Accrued Expenses 6,164 Oct 2017 Dec 2017 0.0514 (268 ) Other Long-Term Liabilities 11. COMMITMENTS AND CONTINGENCIES (Continued) Self-Insurance Liabilities – As of September 30, 2016 , and at various times in the past, the Company self-funded its workers' compensation and employee medical expenses. The Company has established reserves to cover these self-insured liabilities and also maintains stop-loss insurance to limit its exposures under these programs. Claims reserves represent accruals for the estimated uninsured portion of reported claims, including adverse development of reported claims, as well as estimates of incurred but not reported claims. Claims incurred but not reported are estimated based on the Company’s historical experience, which is continually monitored, and accruals are adjusted when warranted by changes in facts and circumstances. The Company’s actual experience may be different than its estimates, sometimes significantly. Changes in assumptions, as well as changes in actual experience could cause these estimates to change. Insurance and claims expense will vary from period to period based on the severity and frequency of claims incurred in a given period. The Company’s self-insurance reserves totaled $6.7 million and $7.9 million as of September 30, 2016 and January 1, 2016, respectively. These accruals are recorded in Accrued Expenses and Other Long-Term Liabilities in the Condensed Consolidated Balance Sheets.

Earnings (Loss) Per Share (EPS)

Earnings (Loss) Per Share (EPS)	9 Months Ended
	Sep. 30, 2016
Earnings Per Share [Abstract]
EARNINGS (LOSS) PER SHARE (EPS)	EARNINGS (LOSS) PER SHARE (“EPS”) The following table illustrates the calculation of basic and diluted EPS (in thousands, except per share amounts): Three Months Ended Nine Months Ended September 30, 2016 October 2, 2015 September 30, 2016 October 2, 2015 Numerator for basic and diluted EPS: Net income (loss) $ 11,458 $ 22 $ (1,972 ) $ 17,313 Denominator for basic EPS: Weighted average shares outstanding 30,782 25,536 30,756 25,424 Effect of dilutive securities: Stock options, restricted stock and restricted stock units 371 905 — 948 Denominator for diluted EPS 31,153 26,441 30,756 26,372 Basic EPS $ 0.37 $ — $ (0.06 ) $ 0.68 Diluted EPS $ 0.37 $ — $ (0.06 ) $ 0.66 The diluted weighted average share calculations do not include the following securities, which are not dilutive to the EPS calculations or the performance criteria have not been met (in thousands): Three Months Ended Nine Months Ended September 30, 2016 October 2, 2015 September 30, 2016 October 2, 2015 Time-vested stock options, restricted stock and restricted stock units 629 260 1,862 268 Performance-vested restricted stock units 373 11 417 10

Accumulated Other Comprehensive

Accumulated Other Comprehensive Income	9 Months Ended
	Sep. 30, 2016
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
ACCUMULATED OTHER COMPREHENSIVE INCOME	ACCUMULATED OTHER COMPREHENSIVE INCOME Accumulated Other Comprehensive Income is comprised of the following (in thousands): Defined Benefit Plan Liability Cash Flow Hedges Foreign Currency Translation Adjustment Total Pre-Tax Amount Tax Net-of-Tax Amount At July 1, 2016 $ (1,179 ) $ (3,746 ) $ 12,668 $ 7,743 $ 1,806 $ 9,549 Unrealized loss on cash flow hedges — (101 ) — (101 ) 35 (66 ) Realized loss on foreign currency hedges — 929 — 929 (324 ) 605 Realized loss on interest rate swap hedges — 50 — 50 (18 ) 32 Foreign currency translation gain — — 3,191 3,191 — 3,191 At September 30, 2016 $ (1,179 ) $ (2,868 ) $ 15,859 $ 11,812 $ 1,499 $ 13,311 Defined Benefit Plan Liability Cash Flow Hedges Foreign Currency Translation Adjustment Total Pre-Tax Amount Tax Net-of-Tax Amount At January 1, 2016 $ (1,179 ) $ (2,392 ) $ 3,609 $ 38 $ 1,332 $ 1,370 Unrealized loss on cash flow hedges — (2,842 ) — (2,842 ) 995 (1,847 ) Realized loss on foreign currency hedges — 2,316 — 2,316 (810 ) 1,506 Realized loss on interest rate swap hedges — 50 — 50 (18 ) 32 Foreign currency translation gain — — 12,250 12,250 — 12,250 At September 30, 2016 $ (1,179 ) $ (2,868 ) $ 15,859 $ 11,812 $ 1,499 $ 13,311 Defined Benefit Plan Liability Cash Flow Hedges Foreign Currency Translation Adjustment Total Pre-Tax Amount Tax Net-of-Tax Amount At July 3, 2015 $ (1,181 ) $ (3,619 ) $ 9,839 $ 5,039 $ 1,784 $ 6,823 Unrealized loss on cash flow hedges — (1,670 ) — (1,670 ) 584 (1,086 ) Realized loss on foreign currency hedges — 562 — 562 (197 ) 365 Realized loss on interest rate swap hedges — 2,169 — 2,169 (759 ) 1,410 Foreign currency translation gain — — 144 144 — 144 At October 2, 2015 $ (1,181 ) $ (2,558 ) $ 9,983 $ 6,244 $ 1,412 $ 7,656 Defined Benefit Plan Liability Cash Flow Hedges Foreign Currency Translation Adjustment Total Pre-Tax Amount Tax Net-of-Tax Amount At January 2, 2015 $ (1,181 ) $ (2,558 ) $ 11,450 $ 7,711 $ 1,412 $ 9,123 Unrealized loss on cash flow hedges — (3,857 ) — (3,857 ) 1,350 (2,507 ) Realized loss on foreign currency hedges — 1,226 — 1,226 (429 ) 797 Realized loss on interest rate swap hedges — 2,631 — 2,631 (921 ) 1,710 Foreign currency translation loss — — (1,467 ) (1,467 ) — (1,467 ) At October 2, 2015 $ (1,181 ) $ (2,558 ) $ 9,983 $ 6,244 $ 1,412 $ 7,656 The realized loss relating to the Company’s foreign currency and interest rate swap hedges were reclassified from Accumulated Other Comprehensive Income and included in Cost of Sales and Interest Expense, Net, respectively, in the Condensed Consolidated Statements of Operations and Comprehensive Income.

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Sep. 30, 2016
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	FAIR VALUE MEASUREMENTS Assets and Liabilities Measured at Fair Value on a Recurring Basis Fair value measurement standards apply to certain financial assets and liabilities that are measured at fair value on a recurring basis (each reporting period). For the Company, these financial assets and liabilities include its derivative instruments. The Company does not have any nonfinancial assets or liabilities that are measured at fair value on a recurring basis. Foreign Currency Contracts – The fair value of foreign currency contracts were determined through the use of cash flow models that utilize observable market data inputs to estimate fair value. These observable market data inputs included foreign exchange rate and credit spread curves. In addition, the Company received fair value estimates from the foreign currency contract counterparties to verify the reasonableness of the Company’s estimates. The Company’s foreign currency contracts are categorized in Level 2 of the fair value hierarchy. The fair value of the Company’s foreign currency contracts will be realized as Cost of Sales as the inventory, which the contracts are hedging the cash flows to produce, is sold, of which approximately $1.7 million is expected to be realized within the next twelve months. Interest Rate Swaps – The fair value of the Company’s interest rate swaps outstanding at September 30, 2016 were determined through the use of a cash flow model that utilizes observable market data inputs. These observable market data inputs include LIBOR, swap rates, and credit spread curves. In addition, the Company received a fair value estimate from the interest rate swaps counterparty to verify the reasonableness of the Company’s estimate. This fair value calculation was categorized in Level 2 of the fair value hierarchy. The fair value of the Company’s interest rate swaps will be realized as Interest Expense as interest on the corresponding borrowings is accrued. The following table provides information regarding assets and liabilities recorded at fair value on a recurring basis (in thousands): Fair Value Measurements Using At Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Description 2016 (Level 1) (Level 2) (Level 3) Assets Interest rate swap (Note 6) $ 75 $ — $ 75 $ — Liabilities Foreign currency contracts (Note 11) $ 1,447 $ — $ 1,447 $ — Interest rate swap (Note 6) $ 974 $ — $ 974 $ — Assets and Liabilities Measured at Fair Value on a Nonrecurring Basis Fair value standards also apply to certain assets and liabilities that are measured at fair value on a nonrecurring basis. The carrying amounts of cash, accounts receivable, accounts payable, and accrued expenses approximate fair value because of the short-term nature of these items. Refer to Note 6 “Debt” for further discussion regarding the fair value of the Company’s Senior Secured Credit Facilities and Senior Notes. A summary of the valuation methodologies for assets and liabilities measured on a nonrecurring basis is as follows: Long-lived Assets – The Company reviews the carrying amount of its long-lived assets to be held and used, other than goodwill and indefinite-lived intangible assets, for potential impairment whenever certain indicators are present such as: a significant decrease in the market price of the asset or asset group; a significant change in the extent or manner in which the long-lived asset or asset group is being used or in its physical condition; a significant change in legal factors or in the business climate that could affect the value of the long-lived asset or asset group, including an action or assessment by a regulator; an accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction; a current-period operating or cash flow loss combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with the use of the long-lived asset or asset group; or a current expectation that, more likely than not, a long-lived asset or asset group will be sold or otherwise disposed of significantly before the end of its previously estimated useful life. The term more likely than not refers to a level of likelihood that is more than 50 percent. 14. FAIR VALUE MEASUREMENTS (Continued) Potential recoverability is measured by comparing the carrying amount of the asset or asset group to its related total future undiscounted cash flows. If the carrying value is not recoverable, the asset or asset group is considered to be impaired. Impairment is measured by comparing the asset or asset group’s carrying amount to its fair value. When it is determined that useful lives are shorter than originally estimated, and no impairment is present, the rate of depreciation is accelerated in order to fully depreciate the assets over their new shorter useful lives. The Company recorded $1.0 million of impairment charges related to its long-lived assets, which is included in Other Operating Expenses, Net during the first nine months of 2016 . The Company did no t record any impairment charges related to its long-lived assets during the first nine months of 2015 . Goodwill and Indefinite-lived Intangible Assets – Goodwill and other indefinite lived intangible assets recorded are not amortized but are periodically tested for impairment. The Company assesses goodwill for impairment on the last day of each fiscal year, or more frequently if certain events occur as described above. Goodwill is evaluated for impairment through the comparison of the fair value of the reporting units to their carrying values. When evaluating goodwill for impairment, the Company may first perform an assessment of qualitative factors to determine if the fair value of the reporting unit is more-likely-than-not greater than its carrying amount. This qualitative assessment is referred to as a “step zero ” approach. If, based on the review of the qualitative factors, the Company determines it is more-likely-than-not that the fair value of the reporting unit is greater than its carrying value, the required two-step impairment test can be bypassed. If the Company does not perform a step zero assessment or if the fair value of the reporting unit is more-likely-than-not less than its carrying value, the Company must perform a two-step impairment test, and calculate the estimated fair value of the reporting unit. If, based upon the two-step impairment test, it is determined that the fair value of a reporting unit is less than its carrying value, an impairment loss is recorded to the extent that the implied fair value of the goodwill within the reporting unit is less than its carrying value. Under the two-step approach, fair values for reporting units are determined based on discounted cash flows and market multiples. Other indefinite lived intangible assets are assessed for impairment on the last day of each fiscal year, or more frequently if certain events occur as described above, by comparing the fair value of the intangible asset to its carrying value. The fair value is determined by using the income approach. The Company did not record any impairment charges related to its indefinite-lived intangible assets, including goodwill, during the first nine months of 2016 or 2015 , respectively. See Note 5 “Intangible Assets” for additional information on the Company’s intangible assets. Cost and Equity Method Investments – The Company holds investments in equity and other securities that are accounted for as either cost or equity method investments, which are classified as Other Assets on the Condensed Consolidated Balance Sheets. The total carrying value of these investments is reviewed quarterly for changes in circumstance or the occurrence of events that suggest the Company’s investment may not be recoverable. The fair value of cost or equity method investments is not adjusted if there are no identified events or changes in circumstances that may have a material effect on the fair value of the investments. Gains and losses realized on cost and equity method investments are recorded in Other Expense (Income), Net, unless separately stated. The aggregate recorded amount of cost and equity method investments at September 30, 2016 and January 1, 2016 was $24.4 million and $20.6 million , respectively. The Company’s equity method investment is in a Chinese venture capital fund focused on investing in life sciences companies. This fund accounts for its investments at fair value with the unrealized change in fair value of these investments recorded as income or loss to the fund in the period of change. As of September 30, 2016 , the Company owned 7.0% of this fund. During the nine month periods ended September 30, 2016 and October 2, 2015 , the Company did not recognize any impairment charges related to its cost method investments. The fair value of these investments is primarily determined by reference to recent sales data of similar shares to independent parties in an inactive market. This fair value calculation is categorized in Level 2 of the fair value hierarchy. During the nine month periods ended September 30, 2016 and October 2, 2015 , the Company recognized a net gain on cost and equity method investments of $0.9 million and $5.1 million , respectively. During the third quarter of 2015, the Company recognized $4.6 million of income from its equity method investment and received a $3.4 million cash distribution, which was classified as a cash flow from operating activities in the Condensed Consolidated Statement of Cash Flows as it represented a return on investment.

Business Segment, Geographic an

Business Segment, Geographic and Concentration Risk Information	9 Months Ended
	Sep. 30, 2016
Segment Reporting [Abstract]
BUSINESS SEGMENT, GEOGRAPHIC AND CONCENTRATION RISK INFORMATION	BUSINESS SEGMENT, GEOGRAPHIC AND CONCENTRATION RISK INFORMATION As a result of the acquisition of Lake Region Medical, the Company has three reportable segments: Greatbatch Medical, QiG and Lake Region Medical. During the first quarter of 2016, the Company completed the Spin-off of a portion of its QiG segment. See Note 2 “Divestiture and Acquisition” for further description of these transactions. As a result of the Lake Region Medical acquisition and the Spin-off, the Company is re-evaluating its internal management and financial reporting structure, which may change its product line and segment reporting in the future. This process is expected to be finalized in 2016. Greatbatch Medical designs and manufactures medical devices and components where Integer either owns the intellectual property or has unique manufacturing and assembly expertise. Greatbatch Medical provides medical devices and components to the cardiac, neuromodulation, orthopedics, portable medical, vascular and energy markets among others. Greatbatch Medical also offers value-added assembly and design engineering services for medical devices that utilize its component products. The QiG segment focuses on the design and development of complete medical device systems and components for our OEM customers. After completion of the Spin-off, the operations of QiG primarily consists of CCC. The medical devices QiG designs and develops are full product solutions that utilize the medical technology expertise and capabilities residing within Greatbatch Medical and Lake Region Medical. QiG revenue consists primarily of sales of various medical device products such as implantable pulse generators, programmer systems, battery chargers, patient wands and leads to medical device companies. Once the medical devices developed by QiG reach significant production levels, the responsibility for manufacturing these products may be transferred to Greatbatch Medical. Lake Region Medical has operated as a segment for Integer since it was acquired during the fourth quarter of 2015. This segment specializes in the design, development, and manufacturing of products across the medical component and device spectrum, primarily serving the cardio, vascular and advanced surgical markets. Lake Region Medical offers fully integrated outsourced manufacturing, regulatory and engineering services, contract manufacturing, finished device assembly services, original device development, and supply chain management. As a result of the Lake Region Medical acquisition and the Spin-off, the Company has recast its product line sales into the following four categories: • Cardio and Vascular: Includes the legacy Greatbatch Vascular product line sales plus the legacy Lake Region Medical Cardio and Vascular product line sales less the legacy Lake Region Medical Cardiac/Neuromodulation sales. Products include introducers, steerable sheaths, guidewires, catheters, and stimulation therapy components, subassemblies and finished devices that deliver therapies for various markets such as coronary and neurovascular disease, peripheral vascular disease, interventional radiology, vascular access, atrial fibrillation, and interventional cardiology, plus products for medical imaging and pharmaceutical delivery. • Cardiac/Neuromodulation: Includes the legacy Greatbatch Cardiac/Neuromodulation and QiG sales plus the legacy Lake Region Medical Cardiac/Neuromodulation sales previously included in their Cardio and Vascular product line sales. Products include batteries, capacitors, filtered and unfiltered feed-throughs, engineered components, implantable stimulation leads, and enclosures used in implantable medical devices. • Advanced Surgical, Orthopedics, and Portable Medical: Includes legacy Greatbatch Orthopedics and Portable Medical product line sales plus the legacy Lake Region Medical Advanced Surgical product line sales. Products include components, sub-assemblies, finished devices, implants, instruments and delivery systems for a range of surgical technologies to the advanced surgical market, including laparoscopy, orthopedics and general surgery, biopsy and drug delivery, joint preservation and reconstruction, arthroscopy, and engineered tubing solutions. Products also include life-saving and life-enhancing applications comprising of automated external defibrillators, portable oxygen concentrators, ventilators, and powered surgical tools. • Electrochem: Includes the legacy Greatbatch Energy, Military and Environmental product line sales. Products include primary (lithium) cells, and primary and secondary battery packs for demanding applications such as down hole drilling tools. 15. BUSINESS SEGMENT, GEOGRAPHIC AND CONCENTRATION RISK INFORMATION (Continued) An analysis and reconciliation of the Company’s business segments, product lines and geographic information to the respective information in the Condensed Consolidated Financial Statements follows. Sales by geographic area are presented by allocating sales from external customers based on where the products are shipped (in thousands): Three Months Ended Nine Months Ended September 30, 2016 October 2, 2015 September 30, 2016 October 2, 2015 Product line sales: Cardio and Vascular $ 148,273 $ 14,107 $ 426,142 $ 37,370 Cardiac/Neuromodulation 95,781 75,577 284,479 248,450 Advanced Surgical, Orthopedics, and Portable Medical 95,190 44,976 290,836 150,795 Electrochem 8,870 11,977 30,361 46,232 Elimination of interproduct line sales (1,547 ) — (4,631 ) — Total sales $ 346,567 $ 146,637 $ 1,027,187 $ 482,847 Three Months Ended Nine Months Ended September 30, 2016 October 2, 2015 September 30, 2016 October 2, 2015 Business segment sales: Greatbatch Medical $ 140,458 $ 144,021 $ 413,231 $ 473,784 QiG 2,708 2,776 8,829 10,564 Lake Region Medical 203,913 — 607,122 — Elimination of intersegment sales (a) (512 ) (160 ) (1,995 ) (1,501 ) Total sales $ 346,567 $ 146,637 $ 1,027,187 $ 482,847 (a) Greatbatch Medical sales include approximately $0.2 million and $0.5 million of intersegment sales for the three and nine months ended September 30, 2016 , respectively. Lake Region Medical sales include approximately $0.3 million and $1.3 million of intersegment sales for the three and nine months ended September 30, 2016 , respectively. Intersegment sales for the three and nine months periods of 2015 are included in the Greatbatch Medical segment. Three Months Ended Nine Months Ended September 30, 2016 October 2, 2015 September 30, 2016 October 2, 2015 Segment income (loss) from operations: Greatbatch Medical $ 15,986 $ 21,512 $ 41,565 $ 72,179 QiG 562 (7,680 ) (5,347 ) (20,132 ) Lake Region Medical 29,906 — 78,461 — Total segment income from operations 46,454 13,832 114,679 52,047 Unallocated operating expenses (9,592 ) (12,637 ) (37,414 ) (28,429 ) Operating income 36,862 1,195 77,265 23,618 Unallocated expenses, net (28,145 ) (1,189 ) (80,623 ) (1,857 ) Income (loss) before provision (benefit) for income taxes $ 8,717 $ 6 $ (3,358 ) $ 21,761 15. BUSINESS SEGMENT, GEOGRAPHIC AND CONCENTRATION RISK INFORMATION (Continued) Three Months Ended Nine Months Ended September 30, 2016 October 2, 2015 September 30, 2016 October 2, 2015 Sales by geographic area: United States $ 206,663 $ 71,545 $ 612,876 $ 217,102 Non-Domestic locations: Puerto Rico 41,745 26,816 120,217 98,247 Belgium 14,256 12,305 52,913 45,690 Rest of world 83,903 35,971 241,181 121,808 Total sales $ 346,567 $ 146,637 $ 1,027,187 $ 482,847 Three customers accounted for a significant portion of the Company’s sales as follows: Three Months Ended Nine Months Ended September 30, 2016 October 2, 2015 September 30, 2016 October 2, 2015 Customer A 18% 17% 18% 20% Customer B 18% 19% 16% 18% Customer C 11% 10% 12% 12% Total 47% 46% 46% 50% Long-lived tangible assets by geographic area are as follows (in thousands): As of September 30, 2016 January 1, 2016 United States $ 263,347 $ 264,556 Rest of world 118,324 114,936 Total $ 381,671 $ 379,492

Impact of Recently Issued Accou

Impact of Recently Issued Accounting Standards	9 Months Ended
	Sep. 30, 2016
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
IMPACT OF RECENTLY ISSUED ACCOUNTING STANDARDS	IMPACT OF RECENTLY ISSUED ACCOUNTING STANDARDS In the normal course of business, management evaluates all new accounting pronouncements issued by the Financial Accounting Standards Board (“FASB”), Securities and Exchange Commission (“SEC”), Emerging Issues Task Force (“EITF”), or other authoritative accounting bodies to determine the potential impact they may have on the Company’s Condensed Consolidated Financial Statements. Based upon this review, except as noted below, management does not expect any of the recently issued accounting pronouncements, which have not already been adopted, to have a material impact on the Company’s Condensed Consolidated Financial Statements. Recently Adopted In September 2015, the FASB issued Accounting Standards Update (“ASU”) 2015-16, “Business Combinations (Topic 805): Simplifying the Accounting for Measurement-Period Adjustments,” which eliminates the requirement for an acquirer in a business combination to account for measurement-period adjustments retrospectively. This update requires acquiring companies to recognize measurement-period adjustments during the period in which they determine the amounts, including the effect on earnings of any amounts they would have recorded in previous periods if the accounting had been completed at the acquisition date. The guidance in this ASU became effective for the Company on January 2, 2016. See Note 2 “Divestiture and Acquisition” for further description of the measurement-period adjustments made and the Company’s acquisition. Not Yet Adopted In August 2016, the FASB issued ASU No. 2016-15 “Statement of Cash Flows (Topic 230): Classification of Certain Cash Receipts and Cash Payments: A Consensus of the FASB Emerging Issues Task Force.” ASU 2016-15 makes targeted changes to how cash receipts and cash payments are presented in the statement of cash flows. The areas specifically addressed include debt prepayment and debt extinguishment costs, the settlement of zero-coupon debt instruments, contingent consideration payments made after a business combination, proceeds from the settlement of insurance claims, cash premiums paid for and proceeds from corporate-owned life insurance policies, distributions received from equity method investees and cash receipts from payments on transferor’s beneficial interest on securitized trade receivables. Additionally, the amendment states that, in the absence of other prevailing guidance, cash receipts and payments that have characteristics of more than one class of cash flows should have each separately identifiable source or use of cash presented within the most predominant class of cash flows based on the nature of the underlying cash flows. These amendments are effective for the Company in annual and interim reporting periods beginning after December 15, 2017, with early adoption permitted. The Company is currently evaluating the impact that the adoption of this ASU will have on its Condensed Consolidated Statements of Cash Flows. In June 2016, the FASB issued ASU No. 2016-13, “Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments,” which amends the guidance on reporting credit losses for assets held at amortized cost and available-for-sale debt securities. For assets held at amortized cost, the ASU eliminates the probable initial recognition threshold and requires an entity to reflect a current estimate of all expected credit losses, such that the net amount expected to be collected is presented. For available-for-sale debt securities, the ASU requires credit losses to be presented as an allowance versus a write-down. These amendments are effective for the Company in annual and interim reporting periods beginning after December 15, 2019, with early adoption permitted in annual and interim reporting periods beginning after December 15, 2018. The Company is currently evaluating the impact that the adoption of this ASU will have on its Condensed Consolidated Financial Statements. In March 2016, the FASB issued ASU 2016-09, “Compensation—Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting.” ASU 2016-09 changes how companies account for certain aspects of share-based payment awards to employees, including the accounting for income taxes, forfeitures and statutory tax withholding requirements, as well as classification in the statement of cash flows. ASU 2016-09 is effective for the Company in annual and interim reporting periods beginning after December 15, 2016, with early adoption permitted. If an entity early adopts in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period and the entity must adopt all of the amendments from ASU 2016-09 in the same period. The Company is currently evaluating the impact that the adoption of this ASU will have on its Condensed Consolidated Financial Statements. 16. IMPACT OF RECENTLY ISSUED ACCOUNTING STANDARDS (Continued) In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842),” which requires companies to recognize all leases as assets and liabilities on the consolidated balance sheet. This ASU retains a distinction between finance leases and operating leases, and the classification criteria for distinguishing between finance leases and operating leases are substantially similar to the classification criteria for distinguishing between capital leases and operating leases in the current accounting literature. As a result, the effect of leases on the consolidated statement of comprehensive income and a consolidated statement of cash flows is largely unchanged from previous GAAP. The amendments in this ASU are effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. Earlier application is permitted. The Company is currently evaluating the impact that the adoption of this ASU will have on its Condensed Consolidated Financial Statements. In January 2016, the FASB issued ASU No. 2016-01, “Financial Instruments - Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities.” This ASU requires equity investments (except those accounted for under the equity method of accounting, or those that result in consolidation of the investee) to be measured at fair value with changes in fair value recognized in net income; requires entities to use the exit price notion when measuring the fair value of financial instruments for disclosure purposes; requires separate presentation of financial assets and financial liabilities by measurement category and form of financial asset; and requires entities to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk (also referred to as “own credit”) when the organization has elected to measure the liability at fair value in accordance with the fair value option. This ASU is effective for public companies for fiscal years beginning after December 15, 2017, including interim periods within those fiscal years. Early adoption of the own credit provision is permitted. The Company is currently evaluating the impact that the adoption of this ASU will have on its Condensed Consolidated Financial Statements. In July 2015, the FASB issued ASU No. 2015-11, “Simplifying the Measurement of Inventory,” which simplifies the subsequent measurement of inventory by requiring inventory to be measured at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. This ASU is effective for public business entities for fiscal years beginning after December 15, 2016, and interim periods within those fiscal years. The Company is currently assessing the impact of adopting this ASU on its Condensed Consolidated Financial Statements. In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers.” The core principle behind ASU No. 2014-09 is that an entity should recognize revenue in an amount that reflects the consideration to which the entity expects to be entitled in exchange for delivering goods and services. In August 2015, the FASB approved a one year deferral to the effective date to be adopted by all public companies for annual reporting periods beginning after December 15, 2017, with earlier application permitted as of annual reporting periods beginning after December 15, 2016. In March, April and May of 2016, respectively, the FASB issued ASU No. 2016-08, which clarifies the implementation guidance on principal versus agent considerations, ASU No. 2016-10, which clarifies the implementation guidance on identifying performance obligations and licensing and ASU No. 2016-12, which provides improvements to the guidance on collectability, non-cash consideration, and completed contracts at transition, a practical expedient for contract modifications at transition and an accounting policy election related to the presentation of sales taxes and other similar taxes collected from customers. These amendments may be applied retrospectively to each prior period presented or retrospectively with the cumulative effect recognized as of the date of initial application. The Company is currently assessing the financial impact of adopting these ASU’s and the methods of adoption; however, given the scope of the new standard, the Company is currently unable to provide a reasonable estimate regarding the financial impact or which method of adoption will be elected.

Summary of Significant Accoun23

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2016
Accounting Policies [Abstract]
Interim Basis of Accounting	The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information (Accounting Standards Codification (“ASC”) 270, Interim Reporting ) and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, these financial statements do not include all of the information necessary for a full presentation of financial position, results of operations, and cash flows in conformity with accounting principles generally accepted in the United States of America (“GAAP”). Operating results for interim periods are not necessarily indicative of results that may be expected for the fiscal year as a whole. In the opinion of management, the condensed consolidated financial statements reflect all adjustments (consisting of normal recurring adjustments) considered necessary for a fair presentation of the results of Integer Holdings Corporation and its subsidiaries (collectively “Integer” or the “Company”) for the periods presented. The January 1, 2016 condensed consolidated balance sheet data was derived from the Company’s audited consolidated financial statements but does not include all disclosures required by GAAP. For further information, refer to the consolidated financial statements and notes included in the Company’s Annual Report on Form 10-K for the year ended January 1, 2016 .
Use of Estimates	The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, certain components of equity, sales, expenses, and related disclosures at the date of the financial statements and during the reporting period. Actual results could differ materially from these estimates.
Fiscal Period	The Company utilizes a fifty-two, fifty-three week fiscal year ending on the Friday nearest December 31. The third quarter and first nine months of 2016 and 2015 each contained 13 weeks and 39 weeks, respectively, and ended on September 30, and October 2, respectively.
Income Taxes	The income tax provision for interim periods is determined using an estimate of the annual effective tax rate, adjusted for discrete items, if any, that are taken into account in the relevant period. Each quarter, the estimate of the annual effective tax rate is updated, and if the estimated effective tax rate changes, a cumulative adjustment is made. There is a potential for volatility of the effective tax rate due to several factors, including discrete items, changes in the mix of the pre-tax income and the jurisdictions to which it relates, changes in tax laws and foreign tax holidays, business reorganizations, settlements with taxing authorities and foreign currency fluctuations.
Long Lived Assets and Finite-Lived Intangible Assets	The Company reviews the carrying amount of its long-lived assets to be held and used, other than goodwill and indefinite-lived intangible assets, for potential impairment whenever certain indicators are present such as: a significant decrease in the market price of the asset or asset group; a significant change in the extent or manner in which the long-lived asset or asset group is being used or in its physical condition; a significant change in legal factors or in the business climate that could affect the value of the long-lived asset or asset group, including an action or assessment by a regulator; an accumulation of costs significantly in excess of the amount originally expected for the acquisition or construction; a current-period operating or cash flow loss combined with a history of operating or cash flow losses or a projection or forecast that demonstrates continuing losses associated with the use of the long-lived asset or asset group; or a current expectation that, more likely than not, a long-lived asset or asset group will be sold or otherwise disposed of significantly before the end of its previously estimated useful life. The term more likely than not refers to a level of likelihood that is more than 50 percent. 14. FAIR VALUE MEASUREMENTS (Continued) Potential recoverability is measured by comparing the carrying amount of the asset or asset group to its related total future undiscounted cash flows. If the carrying value is not recoverable, the asset or asset group is considered to be impaired. Impairment is measured by comparing the asset or asset group’s carrying amount to its fair value. When it is determined that useful lives are shorter than originally estimated, and no impairment is present, the rate of depreciation is accelerated in order to fully depreciate the assets over their new shorter useful lives. The Company recorded $1.0 million of impairment charges related to its long-lived assets, which is included in Other Operating Expenses, Net during the first nine months of 2016 . The Company did no t record any impairment charges related to its long-lived assets during the first nine months of 2015 .
Goodwill and Intangible Assets	Goodwill and other indefinite lived intangible assets recorded are not amortized but are periodically tested for impairment. The Company assesses goodwill for impairment on the last day of each fiscal year, or more frequently if certain events occur as described above. Goodwill is evaluated for impairment through the comparison of the fair value of the reporting units to their carrying values. When evaluating goodwill for impairment, the Company may first perform an assessment of qualitative factors to determine if the fair value of the reporting unit is more-likely-than-not greater than its carrying amount. This qualitative assessment is referred to as a “step zero ” approach. If, based on the review of the qualitative factors, the Company determines it is more-likely-than-not that the fair value of the reporting unit is greater than its carrying value, the required two-step impairment test can be bypassed. If the Company does not perform a step zero assessment or if the fair value of the reporting unit is more-likely-than-not less than its carrying value, the Company must perform a two-step impairment test, and calculate the estimated fair value of the reporting unit. If, based upon the two-step impairment test, it is determined that the fair value of a reporting unit is less than its carrying value, an impairment loss is recorded to the extent that the implied fair value of the goodwill within the reporting unit is less than its carrying value. Under the two-step approach, fair values for reporting units are determined based on discounted cash flows and market multiples. Other indefinite lived intangible assets are assessed for impairment on the last day of each fiscal year, or more frequently if certain events occur as described above, by comparing the fair value of the intangible asset to its carrying value. The fair value is determined by using the income approach.
Cost And Equity Method Investments	The Company holds investments in equity and other securities that are accounted for as either cost or equity method investments, which are classified as Other Assets on the Condensed Consolidated Balance Sheets. The total carrying value of these investments is reviewed quarterly for changes in circumstance or the occurrence of events that suggest the Company’s investment may not be recoverable. The fair value of cost or equity method investments is not adjusted if there are no identified events or changes in circumstances that may have a material effect on the fair value of the investments. Gains and losses realized on cost and equity method investments are recorded in Other Expense (Income), Net, unless separately stated.

Divestiture and Acquisition (Ta

Divestiture and Acquisition (Tables)	9 Months Ended
	Sep. 30, 2016
Divestiture and Acquisition [Abstract]
Summary of divested assets and liabilities	In connection with the Spin-off, during the first quarter of 2016, the Company made a cash capital contribution of $75 million to Nuvectra and divested the following assets and liabilities (in thousands): Assets divested Cash and cash equivalents $ 76,256 Other current assets 977 Property, plant and equipment, net 4,407 Amortizing intangible assets, net 1,931 Goodwill 40,830 Deferred income taxes 6,446 Total assets divested 130,847 Liabilities transferred Current liabilities 2,119 Net assets divested $ 128,728
Summary of Assets Acquired and Liabilities Assumed	The aggregate consideration paid to the stockholders and equity award holders of Lake Region Medical consisted of the following (in thousands): Cash $ 478,490 Fair value of Integer common stock 245,368 Replacement stock options attributable to pre-acquisition service 4,508 Total purchase consideration $ 728,366
Schedule of Recognized Identified Assets Acquired and Liabilities Assumed [Table Text Block]	The following table summarizes the allocation of the Lake Region Medical purchase price to the assets acquired and liabilities assumed (in thousands): Assets acquired Current assets $ 269,815 Property, plant and equipment 216,473 Amortizing intangible assets 849,000 Indefinite-lived intangible assets 70,000 Goodwill 660,670 Other non-current assets 1,629 Total assets acquired 2,067,587 Liabilities assumed Current liabilities 103,986 Debt assumed 1,044,675 Other long-term liabilities 190,560 Total liabilities assumed 1,339,221 Net assets acquired $ 728,366
Schedule of Acquired Finite-Lived Intangible Assets by Major Class [Table Text Block]	Intangible Assets – The purchase price was allocated to intangible assets as follows (dollars in thousands): Amortizing Intangible Assets Fair Value Assigned Weighted Average Amortization Period (Years) Estimated Useful Life (Years) Weighted Average Discount Rate Technology $ 160,000 7 19 11.5% Customer lists 689,000 14 29 11.5% $ 849,000 13 27 11.5% Indefinite-lived Intangible Assets Trademarks and tradenames $ 70,000 N/A N/A 11.5%
Summary of Acquisition Pro Forma Results	The following unaudited pro forma information presents the consolidated results of operations of the Company and Lake Region Medical as if that acquisition occurred as of the beginning of fiscal year 2014 (in thousands, except per share amounts): Three Months Ended Nine Months Ended October 2, 2015 October 2, 2015 Sales $ 349,561 $ 1,085,912 Net loss (9,215 ) (3,540 ) Loss per share: Basic $ (0.30 ) $ (0.12 ) Diluted $ (0.30 ) $ (0.12 )

Supplemental Cash Flow Inform25

Supplemental Cash Flow Information (Tables)	9 Months Ended
	Sep. 30, 2016
Supplemental Cash Flow Elements [Abstract]
Schedule of Cash Flow, Supplemental Disclosures	Nine Months Ended (in thousands) September 30, 2016 October 2, 2015 Noncash investing and financing activities: Property, plant and equipment purchases included in accounts payable $ 5,062 $ 892 Purchase of technology included in accrued expenses 1,000 — Common stock contributed to 401(k) Plan — 3,920 Deferred financing costs included in accounts payable — 7,922 Divestiture of noncash assets 54,591 — Divestiture of liabilities 2,119 —

Inventories (Tables)

Inventories (Tables)	9 Months Ended
	Sep. 30, 2016
Inventory Disclosure [Abstract]
Schedule of Inventory, Current	Inventories are comprised of the following (in thousands): As of September 30, 2016 January 1, 2016 Raw materials $ 114,335 $ 107,296 Work-in-process 99,892 93,729 Finished goods 48,005 51,141 Total $ 262,232 $ 252,166

Intangible Assets (Tables)

Intangible Assets (Tables)	9 Months Ended
	Sep. 30, 2016
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of Finite-Lived Intangible Assets, Major Class	Amortizing intangible assets are comprised of the following (in thousands): Gross Carrying Amount Accumulated Amortization Foreign Currency Translation Net Carrying Amount At September 30, 2016 Purchased technology and patents $ 256,719 $ (96,381 ) $ 2,750 $ 163,088 Customer lists 759,987 (55,416 ) 4,771 709,342 Other 4,534 (5,126 ) 821 229 Total amortizing intangible assets $ 1,021,240 $ (156,923 ) $ 8,342 $ 872,659 At January 1, 2016 Purchased technology and patents $ 255,776 $ (83,708 ) $ 1,444 $ 173,512 Customer lists 761,857 (40,815 ) (986 ) 720,056 Other 4,534 (4,946 ) 821 409 Total amortizing intangible assets $ 1,022,167 $ (129,469 ) $ 1,279 $ 893,977
Schedule of Finite-Lived Intangible Assets, Amortization Expense	Aggregate intangible asset amortization expense is comprised of the following (in thousands): Three Months Ended Nine Months Ended September 30, 2016 October 2, 2015 September 30, 2016 October 2, 2015 Cost of sales $ 4,228 $ 1,324 $ 12,708 $ 4,240 Selling, general and administrative expenses 5,109 1,831 15,368 5,474 Research, development and engineering costs, net 136 88 375 294 Total intangible asset amortization expense $ 9,473 $ 3,243 $ 28,451 $ 10,008
Schedule of Finite-Lived Intangible Assets, Future Amortization Expense	Estimated future intangible asset amortization expense based on the carrying value as of September 30, 2016 is as follows (in thousands): Estimated Amortization Expense Remainder of 2016 $ 9,478 2017 44,129 2018 45,048 2019 45,135 2020 45,734 Thereafter 683,135 Total estimated amortization expense $ 872,659
Schedule of Indefinite-Lived Intangible Assets and Goodwill	Indefinite-lived intangible assets are comprised of the following (in thousands): Trademarks and Tradenames At January 1, 2016 $ 90,288 At September 30, 2016 $ 90,288 5. INTANGIBLE ASSETS (Continued) The change in goodwill is as follows (in thousands): Greatbatch Medical QiG Lake Region Medical Total At January 1, 2016 $ 303,929 $ 50,096 $ 659,545 $ 1,013,570 Goodwill divested (Note 2) — (40,830 ) — (40,830 ) Purchase accounting adjustments (Note 2) — — (1,118 ) (1,118 ) Foreign currency translation 123 — 5,590 5,713 At September 30, 2016 $ 304,052 $ 9,266 $ 664,017 $ 977,335

Debt (Tables)

Debt (Tables)	9 Months Ended
	Sep. 30, 2016
Debt Disclosure [Abstract]
Schedule of Long-Term Debt	Long-term debt is comprised of the following (in thousands): As of September 30, 2016 January 1, 2016 Senior secured term loan A $ 360,938 $ 375,000 Senior secured term loan B 1,017,312 1,025,000 9.125% senior notes due 2023 360,000 360,000 Revolving line of credit 50,000 — Less unamortized discount on term loan B and debt issuance costs (42,086 ) (45,947 ) Total debt 1,746,164 1,714,053 Less current portion of long-term debt 29,000 29,000 Total long-term debt $ 1,717,164 $ 1,685,053
Schedule of Maturities of Long-term Debt	Contractual maturities under the Senior Secured Credit Facilities and Senior Notes for the remainder of 2016 and the five years and thereafter, excluding any discounts or premiums, as of September 30, 2016 are as follows (in thousands): Remaining in 2016 $ 7,250 2017 31,344 2018 40,719 2019 47,750 2020 97,750 Thereafter 1,563,437 Total $ 1,788,250
Schedule of Interest Rate Derivatives	Information regarding the Company’s outstanding interest rate swaps designated as cash flow hedges as of September 30, 2016 is as follows (dollars in thousands): Notional Amount Start Date End Date Pay Fixed Rate Receive Current Floating Rate Fair Value Balance Sheet Location $ 200,000 Jun-17 Jun-20 1.1325 % N/A $ (974 ) Other Long-Term Liabilities $ 250,000 Jul-16 Jun-17 0.615 % 0.53 % $ 75 Prepaid Expenses and Other Current Assets
Schedule of Deferred Financing Fees	The change in deferred debt issuance costs related to the Revolving Credit Facility is as follows (in thousands): At January 1, 2016 $ 4,791 Amortization during the period (745 ) At September 30, 2016 $ 4,046 The change in unamortized discount and debt issuance costs related to the Term Loan Facilities and Senior Notes is as follows (in thousands): Debt Issuance Costs Unamortized Discount on TLB Facility Total At January 1, 2016 $ 35,908 $ 10,039 $ 45,947 Financing costs incurred 781 — 781 Amortization during the period (3,669 ) (973 ) (4,642 ) At September 30, 2016 $ 33,020 $ 9,066 $ 42,086

Benefit Plans (Tables)

Benefit Plans (Tables)	9 Months Ended
	Sep. 30, 2016
Defined Benefit Pension Plans and Defined Benefit Postretirement Plans Disclosure [Abstract]
Schedule of Defined Benefit Plan, Change in Benefit Obligation	The change in net defined benefit plan liability is as follows (in thousands): At January 1, 2016 $ 7,121 Net defined benefit cost 584 Benefit payments (76 ) Foreign currency translation 125 At September 30, 2016 $ 7,754
Schedule of Net Defined Benefit Cost	Net defined benefit cost is comprised of the following (in thousands): Three Months Ended Nine Months Ended September 30, 2016 October 2, 2015 September 30, 2016 October 2, 2015 Service cost $ 108 $ 76 $ 326 $ 233 Interest cost 44 15 132 45 Amortization of net loss 47 13 140 39 Expected return on plan assets (5 ) (2 ) (14 ) (8 ) Net defined benefit cost $ 194 $ 102 $ 584 $ 309

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	9 Months Ended
	Sep. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs	The components and classification of stock-based compensation expense were as follows (in thousands): Three Months Ended Nine Months Ended September 30, 2016 October 2, 2015 September 30, 2016 October 2, 2015 Stock options $ 663 $ 697 $ 1,857 $ 1,979 Restricted stock and restricted stock units 1,554 1,701 5,322 5,081 401(k) Plan stock contribution — 674 — 1,984 Total stock-based compensation expense $ 2,217 $ 3,072 $ 7,179 $ 9,044 Cost of sales $ 158 $ 685 $ 505 $ 2,039 Selling, general and administrative expenses 1,677 1,981 4,860 5,890 Research, development and engineering costs, net 115 361 408 1,070 Other operating expenses, net 267 45 1,406 45 Total stock-based compensation expense $ 2,217 $ 3,072 $ 7,179 $ 9,044
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions	The weighted average fair value and assumptions used to value options granted are as follows: Nine Months Ended September 30, 2016 October 2, 2015 Weighted average fair value $ 9.25 $ 12.18 Risk-free interest rate 1.56 % 1.55 % Expected volatility 26 % 26 % Expected life (in years) 5 5 Expected dividend yield — % — %
Schedule of Share-based Compensation, Stock Options Activity	The following table summarizes the Company’s stock option activity: Number of Stock Options Weighted Average Exercise Price Weighted Average Remaining Contractual Life (In Years) Aggregate Intrinsic Value (In Millions) Outstanding at January 1, 2016 1,678,900 $ 28.32 Granted 245,439 49.58 Exercised (32,833 ) 22.00 Forfeited or expired (91,385 ) 46.13 Adjustment due to Spin-off — (2.02 ) Outstanding at September 30, 2016 1,800,121 $ 28.41 5.8 $ 2.3 Exercisable at September 30, 2016 1,432,312 $ 23.87 5.0 $ 2.3
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity	The following table summarizes time-vested restricted stock and restricted stock unit activity: Time-Vested Activity Weighted Average Fair Value Nonvested at January 1, 2016 39,235 $ 47.40 Granted 48,702 50.15 Vested (15,391 ) 51.39 Forfeited (10,835 ) 48.67 Nonvested at September 30, 2016 61,711 $ 48.35 The following table summarizes performance-vested restricted stock unit activity: Performance- Vested Activity Weighted Average Fair Value Nonvested at January 1, 2016 577,825 $ 25.11 Granted 163,651 31.20 Vested (249,153 ) 15.86 Forfeited (119,005 ) 32.15 Nonvested at September 30, 2016 373,318 $ 31.70

Other Operating Expenses, Net (

Other Operating Expenses, Net (Tables)	9 Months Ended
	Sep. 30, 2016
Restructuring Cost and Reserve [Line Items]
Schedule of Other Operating Cost and Expense By Component	Other Operating Expenses, Net is comprised of the following (in thousands): Three Months Ended Nine Months Ended September 30, 2016 October 2, 2015 September 30, 2016 October 2, 2015 2014 investments in capacity and capabilities $ 4,542 $ 5,116 $ 13,821 $ 17,854 Orthopedic facilities optimization 329 357 628 1,348 Lake Region Medical consolidations 2,908 — 7,355 — Acquisition and integration costs 5,319 5,202 23,143 5,366 Asset dispositions, severance and other 272 3,169 5,057 4,881 $ 13,370 $ 13,844 $ 50,004 $ 29,449
Investments in Capacity and Capabilities [Member]
Restructuring Cost and Reserve [Line Items]
Schedule of Restructuring Reserve By Type of Cost	The change in accrued liabilities related to the 2014 investments in capacity and capabilities is as follows (in thousands): Severance and Retention Accelerated Depreciation/Asset Write-offs Other Total At January 1, 2016 $ 1,429 $ — $ 1,595 $ 3,024 Restructuring charges — 1,787 12,034 13,821 Write-offs — (1,787 ) — (1,787 ) Cash payments (1,246 ) — (13,629 ) (14,875 ) At September 30, 2016 $ 183 $ — $ — $ 183
Orthopaedic Facility Optimization [Member]
Restructuring Cost and Reserve [Line Items]
Schedule of Restructuring Reserve By Type of Cost	The change in accrued liabilities related to the orthopedic facilities optimization is as follows (in thousands): Severance and Retention Accelerated Depreciation/Asset Write-offs Other Total At January 1, 2016 $ — $ — $ — $ — Restructuring charges — 202 426 628 Write-offs — (202 ) — (202 ) Cash payments — (426 ) (426 ) At September 30, 2016 $ — $ — $ — $ —
Legacy Lake Region Medical Consolidation [Member]
Restructuring Cost and Reserve [Line Items]
Schedule of Restructuring Reserve By Type of Cost	The change in accrued liabilities related to the Lake Region Medical consolidation initiatives is as follows (in thousands): Employee Costs Accelerated Depreciation/Asset Write-offs Other Total At January 1, 2016 $ 3,667 $ — $ 596 $ 4,263 Restructuring charges 4,646 907 1,802 7,355 Write-offs — (907 ) — (907 ) Cash payments (7,392 ) — (1,942 ) (9,334 ) At September 30, 2016 $ 921 $ — $ 456 $ 1,377

Commitments and Contingencies (

Commitments and Contingencies (Tables)	9 Months Ended
	Sep. 30, 2016
Commitments and Contingencies Disclosure [Abstract]
Schedule of Product Warranty Liability	The change in product warranty liability was comprised of the following (in thousands):
Schedule of Derivative Instruments, Gain (Loss) in Statement of Financial Performance	The impact to the Company’s results of operations from its forward contract hedges is as follows (in thousands):
Schedule of Foreign Exchange Contracts, Statement of Financial Position	Information regarding outstanding foreign currency contracts designated as cash flow hedges as of September 30, 2016 is as follows (dollars in thousands):

Earnings (Loss) Per Share (EP33

Earnings (Loss) Per Share (EPS) (Tables)	9 Months Ended
	Sep. 30, 2016
Earnings Per Share [Abstract]
Schedule of Calculation of Numerator and Denominator in Earnings Per Share	The following table illustrates the calculation of basic and diluted EPS (in thousands, except per share amounts): Three Months Ended Nine Months Ended September 30, 2016 October 2, 2015 September 30, 2016 October 2, 2015 Numerator for basic and diluted EPS: Net income (loss) $ 11,458 $ 22 $ (1,972 ) $ 17,313 Denominator for basic EPS: Weighted average shares outstanding 30,782 25,536 30,756 25,424 Effect of dilutive securities: Stock options, restricted stock and restricted stock units 371 905 — 948 Denominator for diluted EPS 31,153 26,441 30,756 26,372 Basic EPS $ 0.37 $ — $ (0.06 ) $ 0.68 Diluted EPS $ 0.37 $ — $ (0.06 ) $ 0.66
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share	The diluted weighted average share calculations do not include the following securities, which are not dilutive to the EPS calculations or the performance criteria have not been met (in thousands): Three Months Ended Nine Months Ended September 30, 2016 October 2, 2015 September 30, 2016 October 2, 2015 Time-vested stock options, restricted stock and restricted stock units 629 260 1,862 268 Performance-vested restricted stock units 373 11 417 10

Accumulated Other Comprehensi34

Accumulated Other Comprehensive Income (Tables)	9 Months Ended
	Sep. 30, 2016
Accumulated Other Comprehensive Income (Loss), Net of Tax [Abstract]
Schedule of Accumulated Other Comprehensive Income	Accumulated Other Comprehensive Income is comprised of the following (in thousands): Defined Benefit Plan Liability Cash Flow Hedges Foreign Currency Translation Adjustment Total Pre-Tax Amount Tax Net-of-Tax Amount At July 1, 2016 $ (1,179 ) $ (3,746 ) $ 12,668 $ 7,743 $ 1,806 $ 9,549 Unrealized loss on cash flow hedges — (101 ) — (101 ) 35 (66 ) Realized loss on foreign currency hedges — 929 — 929 (324 ) 605 Realized loss on interest rate swap hedges — 50 — 50 (18 ) 32 Foreign currency translation gain — — 3,191 3,191 — 3,191 At September 30, 2016 $ (1,179 ) $ (2,868 ) $ 15,859 $ 11,812 $ 1,499 $ 13,311 Defined Benefit Plan Liability Cash Flow Hedges Foreign Currency Translation Adjustment Total Pre-Tax Amount Tax Net-of-Tax Amount At January 1, 2016 $ (1,179 ) $ (2,392 ) $ 3,609 $ 38 $ 1,332 $ 1,370 Unrealized loss on cash flow hedges — (2,842 ) — (2,842 ) 995 (1,847 ) Realized loss on foreign currency hedges — 2,316 — 2,316 (810 ) 1,506 Realized loss on interest rate swap hedges — 50 — 50 (18 ) 32 Foreign currency translation gain — — 12,250 12,250 — 12,250 At September 30, 2016 $ (1,179 ) $ (2,868 ) $ 15,859 $ 11,812 $ 1,499 $ 13,311 Defined Benefit Plan Liability Cash Flow Hedges Foreign Currency Translation Adjustment Total Pre-Tax Amount Tax Net-of-Tax Amount At July 3, 2015 $ (1,181 ) $ (3,619 ) $ 9,839 $ 5,039 $ 1,784 $ 6,823 Unrealized loss on cash flow hedges — (1,670 ) — (1,670 ) 584 (1,086 ) Realized loss on foreign currency hedges — 562 — 562 (197 ) 365 Realized loss on interest rate swap hedges — 2,169 — 2,169 (759 ) 1,410 Foreign currency translation gain — — 144 144 — 144 At October 2, 2015 $ (1,181 ) $ (2,558 ) $ 9,983 $ 6,244 $ 1,412 $ 7,656 Defined Benefit Plan Liability Cash Flow Hedges Foreign Currency Translation Adjustment Total Pre-Tax Amount Tax Net-of-Tax Amount At January 2, 2015 $ (1,181 ) $ (2,558 ) $ 11,450 $ 7,711 $ 1,412 $ 9,123 Unrealized loss on cash flow hedges — (3,857 ) — (3,857 ) 1,350 (2,507 ) Realized loss on foreign currency hedges — 1,226 — 1,226 (429 ) 797 Realized loss on interest rate swap hedges — 2,631 — 2,631 (921 ) 1,710 Foreign currency translation loss — — (1,467 ) (1,467 ) — (1,467 ) At October 2, 2015 $ (1,181 ) $ (2,558 ) $ 9,983 $ 6,244 $ 1,412 $ 7,656

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Sep. 30, 2016
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis	The following table provides information regarding assets and liabilities recorded at fair value on a recurring basis (in thousands): Fair Value Measurements Using At Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Description 2016 (Level 1) (Level 2) (Level 3) Assets Interest rate swap (Note 6) $ 75 $ — $ 75 $ — Liabilities Foreign currency contracts (Note 11) $ 1,447 $ — $ 1,447 $ — Interest rate swap (Note 6) $ 974 $ — $ 974 $ —

Business Segment, Geographic 36

Business Segment, Geographic and Concentration Risk Information (Tables)	9 Months Ended
	Sep. 30, 2016
Segment Reconciliation [Abstract]
Reconciliation of Revenue from Segments to Consolidated	Sales by geographic area are presented by allocating sales from external customers based on where the products are shipped (in thousands): Three Months Ended Nine Months Ended September 30, 2016 October 2, 2015 September 30, 2016 October 2, 2015 Product line sales: Cardio and Vascular $ 148,273 $ 14,107 $ 426,142 $ 37,370 Cardiac/Neuromodulation 95,781 75,577 284,479 248,450 Advanced Surgical, Orthopedics, and Portable Medical 95,190 44,976 290,836 150,795 Electrochem 8,870 11,977 30,361 46,232 Elimination of interproduct line sales (1,547 ) — (4,631 ) — Total sales $ 346,567 $ 146,637 $ 1,027,187 $ 482,847 Three Months Ended Nine Months Ended September 30, 2016 October 2, 2015 September 30, 2016 October 2, 2015 Business segment sales: Greatbatch Medical $ 140,458 $ 144,021 $ 413,231 $ 473,784 QiG 2,708 2,776 8,829 10,564 Lake Region Medical 203,913 — 607,122 — Elimination of intersegment sales (a) (512 ) (160 ) (1,995 ) (1,501 ) Total sales $ 346,567 $ 146,637 $ 1,027,187 $ 482,847 (a) Greatbatch Medical sales include approximately $0.2 million and $0.5 million of intersegment sales for the three and nine months ended September 30, 2016 , respectively. Lake Region Medical sales include approximately $0.3 million and $1.3 million of intersegment sales for the three and nine months ended September 30, 2016 , respectively. Intersegment sales for the three and nine months periods of 2015 are included in the Greatbatch Medical segment.
Reconciliation of Operating Profit (Loss) from Segments to Consolidated	Three Months Ended Nine Months Ended September 30, 2016 October 2, 2015 September 30, 2016 October 2, 2015 Segment income (loss) from operations: Greatbatch Medical $ 15,986 $ 21,512 $ 41,565 $ 72,179 QiG 562 (7,680 ) (5,347 ) (20,132 ) Lake Region Medical 29,906 — 78,461 — Total segment income from operations 46,454 13,832 114,679 52,047 Unallocated operating expenses (9,592 ) (12,637 ) (37,414 ) (28,429 ) Operating income 36,862 1,195 77,265 23,618 Unallocated expenses, net (28,145 ) (1,189 ) (80,623 ) (1,857 ) Income (loss) before provision (benefit) for income taxes $ 8,717 $ 6 $ (3,358 ) $ 21,761
Geographic Areas, Revenues from External Customers [Abstract]
Schedule of Revenue From External Customers Attributed to Foreign Countries By Geographic Area	Three Months Ended Nine Months Ended September 30, 2016 October 2, 2015 September 30, 2016 October 2, 2015 Sales by geographic area: United States $ 206,663 $ 71,545 $ 612,876 $ 217,102 Non-Domestic locations: Puerto Rico 41,745 26,816 120,217 98,247 Belgium 14,256 12,305 52,913 45,690 Rest of world 83,903 35,971 241,181 121,808 Total sales $ 346,567 $ 146,637 $ 1,027,187 $ 482,847
Schedule of Revenue By Major Customers By Reporting Segments	Three customers accounted for a significant portion of the Company’s sales as follows: Three Months Ended Nine Months Ended September 30, 2016 October 2, 2015 September 30, 2016 October 2, 2015 Customer A 18% 17% 18% 20% Customer B 18% 19% 16% 18% Customer C 11% 10% 12% 12% Total 47% 46% 46% 50%
Geographic Areas, Long-Lived Assets [Abstract]
Schedule of Long-Lived Assets By Geographical Areas	Long-lived tangible assets by geographic area are as follows (in thousands): As of September 30, 2016 January 1, 2016 United States $ 263,347 $ 264,556 Rest of world 118,324 114,936 Total $ 381,671 $ 379,492

Summary of Significant Accoun37

Summary of Significant Accounting Policies (Basis of Presentation) (Details) - Segment	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Oct. 02, 2015	Sep. 30, 2016	Oct. 02, 2015
Accounting Policies [Abstract]
Fiscal Period Duration	91 days	91 days	273 days	273 days
Number of Reportable Segments			3

Divestiture and Acquisition (Sp

Divestiture and Acquisition (Spin-off of Nuvectra Corporation) (Details) $ in Thousands	Mar. 14, 2016USD ($)	Apr. 01, 2016USD ($)	Oct. 02, 2015USD ($)	Oct. 02, 2015USD ($)	Sep. 30, 2016USD ($)	Jan. 01, 2016USD ($)
Liabilities transferred
Accounts receivable, net					$ 191,409	$ 207,342
Nuvectra [Member]
Liabilities transferred
Accounts receivable, net					$ 7,000
Spin-off [Member] | Nuvectra [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Stock conversion ratio	3
Cash capital contribution		$ 75,000
Assets divested
Cash and cash equivalents	$ 76,256
Other current assets	977
Property, plant and equipment, net	4,407
Amortizing intangible assets, net	1,931
Goodwill	40,830
Deferred income taxes	6,446
Total assets	130,847
Liabilities transferred
Current liabilities	2,119
Net assets divested	$ 128,728
Pre-tax loss		$ 5,200	$ 7,000	$ 18,700

Divestiture and Acquisition (Su

Divestiture and Acquisition (Summary of Assets Acquired and Liabilities Assumed) (Details) - USD ($) $ in Thousands	Oct. 27, 2015	Sep. 30, 2016	Jan. 01, 2016
Assets acquired
Goodwill		$ 977,335	$ 1,013,570
Lake Region Medical [Member]
Business Acquisition [Line Items]
Cash	$ 478,490
Total purchase consideration	728,366
Assets acquired
Current assets	269,815
Property, plant and equipment	216,473
Amortizing intangible assets	849,000
Indefinite-lived intangible assets	70,000
Goodwill	660,670
Other non-current assets	1,629
Total assets acquired	2,067,587
Liabilities assumed
Current liabilities	103,986
Debt assumed	1,044,675
Other long-term liabilities	190,560
Total liabilities assumed	1,339,221
Net assets acquired	728,366
Common Stock [Member] | Lake Region Medical [Member]
Business Acquisition [Line Items]
Equity interests	245,368
Stock Option [Member] | Lake Region Medical [Member]
Business Acquisition [Line Items]
Equity interests	$ 4,508

Divestiture and Acquisition (40

Divestiture and Acquisition (Summary of Finite-Lived Intangible Assets Acquired) (Details) - USD ($) $ in Thousands	Oct. 27, 2015	Apr. 01, 2016
Acquired Finite-Lived Intangible Assets [Line Items]
Weighted Average Amortization Period (Years)		15 years
Lake Region Medical [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Fair Value Assigned	$ 849,000
Weighted Average Amortization Period (Years)	13 years
Finite-Lived Intangible Asset, Useful Life	27 years
Weighted Average Discount Rate	11.50%
Lake Region Medical [Member] | Trademarks And Tradenames [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Indefinite-lived Intangible Assets Acquired	$ 70,000
Acquired Indefinite Lived Intangible Asset Weighted Average Discount Rate	11.50%
Lake Region Medical [Member] | Trademarks And Tradenames [Member] | Minimum [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Royalty Rate (Percent)	0.25%
Lake Region Medical [Member] | Trademarks And Tradenames [Member] | Maximum [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Royalty Rate (Percent)	1.00%
Lake Region Medical [Member] | Technology And Patents [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Fair Value Assigned	$ 160,000
Weighted Average Amortization Period (Years)	7 years
Finite-Lived Intangible Asset, Useful Life	19 years
Weighted Average Discount Rate	11.50%
Lake Region Medical [Member] | Technology And Patents [Member] | Minimum [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Royalty Rate (Percent)	0.50%
Lake Region Medical [Member] | Technology And Patents [Member] | Maximum [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Royalty Rate (Percent)	7.00%
Lake Region Medical [Member] | Customer Lists [Member]
Acquired Finite-Lived Intangible Assets [Line Items]
Fair Value Assigned	$ 689,000
Weighted Average Amortization Period (Years)	14 years
Finite-Lived Intangible Asset, Useful Life	29 years
Weighted Average Discount Rate	11.50%
Customer Annual Attrition Rate	5.00%

Divestiture and Acquisition (41

Divestiture and Acquisition (Summary of Acquisition Pro Forma Results) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	9 Months Ended
	Oct. 02, 2015	Oct. 02, 2015
Business Acquisition [Line Items]
Sales	$ 349,561	$ 1,085,912
Net loss	$ (9,215)	$ (3,540)
Loss per share:
Basic (in dollars per share)	$ (0.30)	$ (0.12)
Diluted (in dollars per share)	$ (0.30)	$ (0.12)

Divestiture and Acquisition (Na

Divestiture and Acquisition (Narrative) (Details) - USD ($) $ in Thousands	Oct. 27, 2015	Sep. 30, 2016
Business Acquisition [Line Items]
Goodwill, measurement-period adjustment		$ (1,118)
Lake Region Medical [Member]
Business Acquisition [Line Items]
Total purchase price and debt assumed	$ 1,770,000
Repayments of Debt	$ 1,000,000
Reason for Acquisition	The Company believes that the combination of Greatbatch and Lake Region Medical brings together two highly complementary organizations that can provide a new level of industry leading capabilities and services to OEM customers while building value for stockholders.
Goodwill, measurement-period adjustment		(1,100)
Deferred Tax Liability, measurement-period adjustment		(2,600)
Revenue since acquisition		607,100
Net loss since acquisition		$ 27,900
Increase in Inventory	$ 23,000

Supplemental Cash Flow Inform43

Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Oct. 02, 2015
Noncash investing and financing activities:
Property, plant and equipment purchases included in accounts payable	$ 5,062	$ 892
Purchase of technology included in accrued expenses	1,000	0
Common stock contributed to 401(k) Plan	0	3,920
Deferred financing costs included in accounts payable	0	7,922
Divestiture of noncash assets	54,591	0
Divestiture of liabilities	$ 2,119	$ 0

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Jan. 01, 2016
Inventory Disclosure [Abstract]
Raw materials	$ 114,335	$ 107,296
Work-in-process	99,892	93,729
Finished goods	48,005	51,141
Total	$ 262,232	$ 252,166

Intangible Assets (Schedule of

Intangible Assets (Schedule of Finite-Lived Intangible Assets, Major Class) (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Jan. 01, 2016
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	$ 1,021,240	$ 1,022,167
Finite-Lived Intangible Assets, Accumulated Amortization	(156,923)	(129,469)
Foreign Currency Translation	8,342	1,279
Total estimated amortization expense	872,659	893,977
Purchased Technology And Patents [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	256,719	255,776
Finite-Lived Intangible Assets, Accumulated Amortization	(96,381)	(83,708)
Foreign Currency Translation	2,750	1,444
Total estimated amortization expense	163,088	173,512
Customer Lists [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	759,987	761,857
Finite-Lived Intangible Assets, Accumulated Amortization	(55,416)	(40,815)
Foreign Currency Translation	4,771	(986)
Total estimated amortization expense	709,342	720,056
Other Intangible Assets [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Gross	4,534	4,534
Finite-Lived Intangible Assets, Accumulated Amortization	(5,126)	(4,946)
Foreign Currency Translation	821	821
Total estimated amortization expense	$ 229	$ 409

Intangible Assets (Schedule o46

Intangible Assets (Schedule of Finite-Lived Intangible Assets, Amortization Expense) (Details) - USD ($) $ in Thousands	3 Months Ended			9 Months Ended
	Sep. 30, 2016	Apr. 01, 2016	Oct. 02, 2015	Sep. 30, 2016	Oct. 02, 2015
Finite-Lived Intangible Assets [Line Items]
Acquired Finite-Lived Intangible Asset		$ 2,000
Weighted Average Amortization Period (Years)		15 years
Finite Lived Intangible Assets, Amortization Expense	$ 9,473		$ 3,243	$ 28,451	$ 10,008
Cost of Sales [Member]
Finite-Lived Intangible Assets [Line Items]
Finite Lived Intangible Assets, Amortization Expense	4,228		1,324	12,708	4,240
Selling General And Administrative Expense [Member]
Finite-Lived Intangible Assets [Line Items]
Finite Lived Intangible Assets, Amortization Expense	5,109		1,831	15,368	5,474
Research and Development Expense [Member]
Finite-Lived Intangible Assets [Line Items]
Finite Lived Intangible Assets, Amortization Expense	$ 136		$ 88	$ 375	$ 294

Intangible Assets (Schedule o47

Intangible Assets (Schedule of Finite-Lived Intangible Assets, Future Amortization Expense) (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Jan. 01, 2016
Finite-Lived Intangible Assets, Amortization Expense, Maturity Schedule [Abstract]
Remainder of 2016	$ 9,478
2,017	44,129
2,018	45,048
2,019	45,135
2,020	45,734
Thereafter	683,135
Total estimated amortization expense	$ 872,659	$ 893,977

Intangible Assets (Schedule o48

Intangible Assets (Schedule of Indefinite-Lived Intangible Assets and Goodwill) (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2016USD ($)
Indefinite-Lived Intangible Assets [Roll Forward]
Indefinite-Lived Intangible Assets (Excluding Goodwill), Beginning	$ 90,288
Indefinite-Lived Intangible Assets (Excluding Goodwill), Ending	90,288
Goodwill [Roll Forward]
Goodwill	1,013,570
Goodwill divested	40,830
Purchase accounting adjustment	(1,118)
Foreign currency translation	5,713
Goodwill	977,335
Greatbatch Medical [Member]
Goodwill [Roll Forward]
Goodwill	303,929
Goodwill divested	0
Purchase accounting adjustment	0
Foreign currency translation	123
Goodwill	304,052
QiG [Member]
Goodwill [Roll Forward]
Goodwill	50,096
Goodwill divested	40,830
Purchase accounting adjustment	0
Foreign currency translation	0
Goodwill	9,266
Lake Region Medical [Member]
Goodwill [Roll Forward]
Goodwill	659,545
Goodwill divested	0
Purchase accounting adjustment	(1,118)
Foreign currency translation	5,590
Goodwill	664,017
Trademarks And Tradenames [Member]
Indefinite-Lived Intangible Assets [Roll Forward]
Indefinite-Lived Intangible Assets (Excluding Goodwill), Beginning	90,288
Indefinite-Lived Intangible Assets (Excluding Goodwill), Ending	$ 90,288

Debt (Schedule of Long-Term Deb

Debt (Schedule of Long-Term Debt) (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Jan. 01, 2016
Debt Instrument [Line Items]
Long-term Debt, Gross	$ 1,788,250
Less unamortized discount on term loan B and debt issuance costs	(42,086)	$ (45,947)
Total debt	1,746,164	1,714,053
Less current portion of long-term debt	29,000	29,000
Total long-term debt	1,717,164	1,685,053
Secured Debt [Member] | Loans Payable [Member] | Term Loan A (TLA) Facility [Member]
Debt Instrument [Line Items]
Long-term Debt, Gross	360,938	375,000
Secured Debt [Member] | Loans Payable [Member] | Term Loan B (TLB) Facility [Member]
Debt Instrument [Line Items]
Long-term Debt, Gross	1,017,312	1,025,000
Secured Debt [Member] | Loans Payable [Member] | 9.125% Senior Notes due 2023 [Member]
Debt Instrument [Line Items]
Long-term Debt, Gross	360,000	360,000
Secured Debt [Member] | Revolving Credit Facility [Member] | New Revolving Credit Facility 2015 [Member]
Debt Instrument [Line Items]
Long-term Debt, Gross	$ 50,000	$ 0

Debt (Credit Facility) (Details

Debt (Credit Facility) (Details)	Oct. 27, 2015USD ($)loan_facility	Sep. 30, 2016USD ($)	Apr. 27, 2016USD ($)
Debt Instrument [Line Items]
Debt Weighted Average Interest Rate		5.69%
Senior Notes [Member] | 9.125% Senior Notes due 2023 [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 360,000,000
Debt Instrument, Maturity Date	Nov. 1, 2023
Long-term Debt, Fair Value		$ 351,000,000
Debt Instrument, Interest Rate, Stated Percentage	9.125%
Senior Notes [Member] | 9.125% Senior Notes due 2023 [Member] | Debt Instrument, Redemption, Period One [Member]
Debt Instrument [Line Items]
Debt Instrument, Redemption Price, Percentage Excluding Make Whole Premium	100.00%
Debt Instrument, Redemption Price, Percentage of Principal Amount Redeemed, Using Proceeds From Equity Offerings	40.00%
Debt Instrument, Redemption Price, Percentage, Using Proceeds From Equity Offerings	109.125%
Secured Debt [Member] | Senior Secured Credit Facilities [Member]
Debt Instrument [Line Items]
Debt Instrument, Covenant Compliance, Collateral, Percentage Of Present And Future Voting Capital Shares Of First Tier Foreign Subsidiaries	66.00%
Secured Debt [Member] | Revolving Credit Facility [Member] | New Revolving Credit Facility 2015 [Member]
Debt Instrument [Line Items]
Credit Facility Maximum Borrowing Capacity	$ 200,000,000
Debt Instrument, Maturity Date	Oct. 27, 2020
Revolving line of credit		50,000,000
Line of Credit Facility, Remaining Borrowing Capacity		141,100,000
Letters of Credit Outstanding, Amount		8,900,000
Secured Debt [Member] | Loans Payable [Member]
Debt Instrument [Line Items]
Debt Instrument, Covenant Compliance, Number Of Additional Term Loan Facilities That May Be Added | loan_facility	1
Secured Debt [Member] | Loans Payable [Member] | Term Loan A (TLA) Facility [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 375,000,000
Debt Instrument, Maturity Date	Oct. 27, 2021
Debt Instrument, Covenant Compliance, Maximum Leverage Ratio	6.50
Debt Instrument, Covenant Compliance, Adjusted EBITDA To Interest Expense Ratio	3
Secured Debt [Member] | Loans Payable [Member] | Term Loan B (TLB) Facility [Member]
Debt Instrument [Line Items]
Debt Instrument, Face Amount	$ 1,025,000,000
Debt Instrument, Discount, Percentage	1.00%
Debt Instrument, Maturity Date	Oct. 27, 2022
Long-term Debt, Fair Value		$ 1,005,000,000
Secured Debt [Member] | Loans Payable [Member] | Term Loan B (TLB) Facility [Member] | Prime Rate [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate	3.25%
Secured Debt [Member] | Loans Payable [Member] | Term Loan B (TLB) Facility [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate	4.25%
Debt Instrument, Interest Rate, Floor	1.00%
Secured Debt [Member] | Swingline Loans [Member] | New Revolving Credit Facility 2015 [Member]
Debt Instrument [Line Items]
Credit Facility Maximum Borrowing Capacity	$ 15,000,000
Secured Debt [Member] | Standby Letters of Credit [Member] | New Revolving Credit Facility 2015 [Member]
Debt Instrument [Line Items]
Credit Facility Maximum Borrowing Capacity			$ 25,000,000
Secured Debt [Member] | Minimum [Member] | Revolving Credit Facility [Member] | New Revolving Credit Facility 2015 [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage	0.175%
Secured Debt [Member] | Minimum [Member] | Loans Payable [Member] | Term Loan A (TLA) Facility [Member] | Prime Rate [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate	0.75%
Secured Debt [Member] | Minimum [Member] | Loans Payable [Member] | Term Loan A (TLA) Facility [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate	1.75%
Secured Debt [Member] | Maximum [Member] | Senior Secured Credit Facilities [Member]
Debt Instrument [Line Items]
Debt Instrument, Covenant Compliance, First Lien Net Leverage Ratio	4.25
Secured Debt [Member] | Maximum [Member] | Revolving Credit Facility [Member] | New Revolving Credit Facility 2015 [Member]
Debt Instrument [Line Items]
Line of Credit Facility, Unused Capacity, Commitment Fee Percentage	0.25%
Secured Debt [Member] | Maximum [Member] | Loans Payable [Member]
Debt Instrument [Line Items]
Debt Instrument, Covenant Compliance, First Lien Net Leverage Ratio	4.25
Secured Debt [Member] | Maximum [Member] | Loans Payable [Member] | Term Loan A (TLA) Facility [Member] | Prime Rate [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate	2.25%
Secured Debt [Member] | Maximum [Member] | Loans Payable [Member] | Term Loan A (TLA) Facility [Member] | London Interbank Offered Rate (LIBOR) [Member]
Debt Instrument [Line Items]
Debt Instrument, Basis Spread on Variable Rate	3.25%

Debt (Long-term Debt Maturity S

Debt (Long-term Debt Maturity Schedule) (Details) $ in Thousands	Sep. 30, 2016USD ($)
Debt Disclosure [Abstract]
Remaining in 2016	$ 7,250
2,017	31,344
2,018	40,719
2,019	47,750
2,020	97,750
Thereafter	1,563,437
Total	$ 1,788,250

Debt (Schedule of Interest Rate

Debt (Schedule of Interest Rate Swaps and Details) (Details) - USD ($)	1 Months Ended		3 Months Ended		9 Months Ended		12 Months Ended
	Jul. 31, 2016	Jun. 30, 2016	Sep. 30, 2016	Oct. 02, 2015	Sep. 30, 2016	Oct. 02, 2015	Jan. 01, 2016	Dec. 28, 2012	Apr. 01, 2016	Apr. 03, 2015
Derivative [Line Items]
Interest Expense			$ 27,870,000	$ 5,825,000	$ 83,395,000	$ 8,151,000
Interest Rate Swap 4 [Member]
Derivative [Line Items]
Derivative, Term of Contract	1 year
Notional Amount, Asset	$ 250,000,000		$ 250,000,000		$ 250,000,000
Pay Fixed Rate			0.615%		0.615%
Receive Current Floating Rate			0.53%		0.53%
Fair Value, Asset			$ 75,000		$ 75,000
Interest Rate Swap 3 [Member]
Derivative [Line Items]
Derivative, Term of Contract		3 years
Notional Amount		$ 200,000,000	$ 200,000,000		$ 200,000,000
Pay Fixed Rate			1.1325%		1.1325%
Fair Value			$ (974,000)		$ (974,000)
Interest Rate Swap 1 [Member]
Derivative [Line Items]
Derivative, Term of Contract								3 years
Notional Amount								$ 150,000,000
Annual Notional Amortizing Amount								$ 50,000,000
Interest Rate Swap [Member]
Derivative [Line Items]
Description Of Interest Rate Cash Flow Hedge Accounting Method							These swaps were accounted for as cash flow hedges.
Gain (Loss) Recognized In Income Ineffective Portion					0	0
Interest Expense					$ 50,000	$ 3,500,000
Interest Rate Swap 2a [Member]
Derivative [Line Items]
Notional Amount										$ 45,000,000
Interest Rate Swap 2b [Member]
Derivative [Line Items]
Notional Amount									$ 45,000,000

Debt (Schedule of Deferred Fina

Debt (Schedule of Deferred Financing Fees) (Details) - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2016	Oct. 02, 2015
Deferred Finance Costs [Roll Forward]
Total, Beginning Balance	$ (45,947)
Amortization during the period	(5,387)	$ (5,368)
Total, Beginning Balance	42,086
Revolving Credit Facility [Member]
Deferred Finance Costs [Roll Forward]
Deferred Finance Costs, Net, Beginning Balance	4,791
Amortization during the period	(745)
Deferred Finance Costs, Net, Ending Balance	4,046
Term Loan And Senior Notes [Member]
Deferred Finance Costs [Roll Forward]
Deferred Finance Costs, Net, Beginning Balance	35,908
Financing costs deferred	781
Amortization during the period	(3,669)
Deferred Finance Costs, Net, Ending Balance	33,020
Total, Beginning Balance	(45,947)
Financing costs incurred	781
Amortization during the period	(4,642)
Total, Beginning Balance	42,086
Term Loan B (TLB) Facility [Member]
Deferred Finance Costs [Roll Forward]
Unamortized Discount on TLB Facility, Beginning Balance	10,039
Financing costs incurred	0
Amortization during the period	(973)
Unamortized Discount on TLB Facility, Ending Balance	$ 9,066

Benefit Plans (Schedule of Defi

Benefit Plans (Schedule of Defined Benefit Plan, Change in Benefit Obligation) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Oct. 02, 2015	Sep. 30, 2016	Oct. 02, 2015
Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]
At January 1, 2016			$ 7,121
Net defined benefit cost	$ 194	$ 102	584	$ 309
Benefit payments			(76)
Foreign currency translation			125
At September 30, 2016	$ 7,754		$ 7,754

Benefit Plans (Schedule of Net

Benefit Plans (Schedule of Net Defined Benefit Cost) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Oct. 02, 2015	Sep. 30, 2016	Oct. 02, 2015
Defined Benefit Pension Plans and Defined Benefit Postretirement Plans Disclosure [Abstract]
Service cost	$ 108	$ 76	$ 326	$ 233
Interest cost	44	15	132	45
Amortization of net loss	47	13	140	39
Expected return on plan assets	(5)	(2)	(14)	(8)
Net defined benefit cost	$ 194	$ 102	$ 584	$ 309

Stock-Based Compensation (Alloc

Stock-Based Compensation (Allocation of Recognized Period Costs) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Oct. 02, 2015	Sep. 30, 2016	Oct. 02, 2015
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	$ 2,217	$ 3,072	$ 7,179	$ 9,044
Stock Option [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	663	697	1,857	1,979
Restricted Stock And Unit Awards [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	1,554	1,701	5,322	5,081
Retirement Plan [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	0	674	0	1,984
Cost of Sales [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	158	685	505	2,039
Selling General And Administrative Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	1,677	1,981	4,860	5,890
Research and Development Expense [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	115	361	408	1,070
Other Operating Income (Expense) [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Allocated Share-based Compensation Expense	$ 267	$ 45	$ 1,406	$ 45

Stock-Based Compensation (Valua

Stock-Based Compensation (Valuation Assumptions) (Details) - $ / shares	9 Months Ended
	Sep. 30, 2016	Oct. 02, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Weighted average fair value	$ 9.25	$ 12.18
Risk-free interest rate	1.56%	1.55%
Expected volatility	26.00%	26.00%
Expected life (in years)	5 years	5 years
Expected dividend yield	0.00%	0.00%

Stock-Based Compensation (Stock

Stock-Based Compensation (Stock Options Activity) (Details) $ / shares in Units, $ in Millions	9 Months Ended
	Sep. 30, 2016USD ($)$ / sharesshares
Stock Option Activity (in shares)
Options Outstanding, Beginning | shares	1,678,900
Granted | shares	245,439
Exercised | shares	(32,833)
Forfeited or expired | shares	(91,385)
Adjustment due to Spin-off, Number of Shares | shares	0
Options Outstanding, Ending | shares	1,800,121
Options Exercisable | shares	1,432,312
Weighted Average Exercise Price (in dollars per share)
Options Outstanding, Beginning | $ / shares	$ 28.32
Granted | $ / shares	49.58
Exercised | $ / shares	22
Forfeited or expired | $ / shares	46.13
Adjustment due to Spin-off, Weighted Average Exercise Price | $ / shares	(2.02)
Options Outstanding, Ending | $ / shares	28.41
Options Exercisable | $ / shares	$ 23.87
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Options Outstanding, Weighted Average Remaining Contractual Term	5 years 9 months 18 days
Options Exercisable, Weighted Average Remaining Contractual Term	5 years
Options Outstanding, Intrinsic Value | $	$ 2.3
Options Exercisable, Intrinsic Value | $	$ 2.3

Stock-Based Compensation (Restr

Stock-Based Compensation (Restricted Stock and Restricted Stock Units Activity) (Details)	9 Months Ended
	Sep. 30, 2016$ / sharesshares
Restricted Stock And Restricted Stock Units Time Based [Member]
Restricted Stock and Restricted Stock Unit Activity (in shares)
Nonvested, Beginning | shares	39,235
Granted | shares	48,702
Vested | shares	(15,391)
Forfeited | shares	(10,835)
Nonvested, Ending | shares	61,711
Restricted Stock and Restricted Stock Unit Weighted Average Fair Value (in dollars per share)
Nonvested, Beginning | $ / shares	$ 47.40
Granted | $ / shares	50.15
Vested | $ / shares	51.39
Forfeited | $ / shares	48.67
Nonvested, Ending | $ / shares	$ 48.35
Restricted Stock And Restricted Stock Units Performance Based [Member]
Restricted Stock and Restricted Stock Unit Activity (in shares)
Nonvested, Beginning | shares	577,825
Granted | shares	163,651
Vested | shares	(249,153)
Forfeited | shares	(119,005)
Nonvested, Ending | shares	373,318
Restricted Stock and Restricted Stock Unit Weighted Average Fair Value (in dollars per share)
Nonvested, Beginning | $ / shares	$ 25.11
Granted | $ / shares	31.20
Vested | $ / shares	15.86
Forfeited | $ / shares	32.15
Nonvested, Ending | $ / shares	$ 31.70

Stock-Based Compensation (Impac

Stock-Based Compensation (Impact of Spin-off) (Details) (Details) $ in Millions	Mar. 14, 2016	Apr. 01, 2016USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Acceleration of remaining compensation expense		$ 0.5
Adjusted Exercise Price due to Spin-off, percentage		93.00%
Spin-off [Member] | Nuvectra [Member]
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Stockholders' Equity Note, Stock Split, Conversion Ratio	3

Other Operating Expenses, Net61

Other Operating Expenses, Net (Schedule of Other Operating Cost and Expense By Component) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Oct. 02, 2015	Sep. 30, 2016	Oct. 02, 2015
Other Operating Income Expense Detail [Line Items]
Other Cost and Expense, Operating	$ 13,370	$ 13,844	$ 50,004	$ 29,449
Investments in Capacity and Capabilities [Member]
Other Operating Income Expense Detail [Line Items]
Other Cost and Expense, Operating	4,542	5,116	13,821	17,854
Orthopaedic Facility Optimization [Member]
Other Operating Income Expense Detail [Line Items]
Other Cost and Expense, Operating	329	357	628	1,348
Legacy Lake Region Medical Consolidation [Member]
Other Operating Income Expense Detail [Line Items]
Other Cost and Expense, Operating	2,908	0	7,355	0
Acquisition And Integration Costs [Member]
Other Operating Income Expense Detail [Line Items]
Other Cost and Expense, Operating	5,319	5,202	23,143	5,366
Asset Dispositions Severance And Other [Member]
Other Operating Income Expense Detail [Line Items]
Other Cost and Expense, Operating	$ 272	$ 3,169	$ 5,057	$ 4,881

Other Operating Expenses, Net62

Other Operating Expenses, Net (Schedule of Restructuring Reserve By Type of Cost) (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2016USD ($)
Orthopaedic Facility Optimization [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance	$ 0
Restructuring charges	628
Write-offs	(202)
Cash payments	(426)
Restructuring Reserve, Ending Balance	0
Legacy Lake Region Medical Consolidation [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance	4,263
Restructuring charges	7,355
Write-offs	(907)
Cash payments	(9,334)
Restructuring Reserve, Ending Balance	1,377
Investments in Capacity and Capabilities [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance	3,024
Restructuring charges	13,821
Write-offs	(1,787)
Cash payments	(14,875)
Restructuring Reserve, Ending Balance	183
Employee Severance [Member] | Legacy Lake Region Medical Consolidation [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance	3,667
Restructuring charges	4,646
Write-offs	0
Cash payments	(7,392)
Restructuring Reserve, Ending Balance	921
Severance And Retention [Member] | Orthopaedic Facility Optimization [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance	0
Restructuring charges	0
Write-offs	0
Cash payments	0
Restructuring Reserve, Ending Balance	0
Severance And Retention [Member] | Investments in Capacity and Capabilities [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance	1,429
Restructuring charges	0
Write-offs	0
Cash payments	(1,246)
Restructuring Reserve, Ending Balance	183
Accelerated Depreciation And Asset Write Offs [Member] | Orthopaedic Facility Optimization [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance	0
Restructuring charges	202
Write-offs	(202)
Cash payments
Restructuring Reserve, Ending Balance	0
Accelerated Depreciation And Asset Write Offs [Member] | Legacy Lake Region Medical Consolidation [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance	0
Restructuring charges	907
Write-offs	(907)
Cash payments	0
Restructuring Reserve, Ending Balance	0
Accelerated Depreciation And Asset Write Offs [Member] | Investments in Capacity and Capabilities [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance	0
Restructuring charges	1,787
Write-offs	(1,787)
Cash payments	0
Restructuring Reserve, Ending Balance	0
Other Restructuring [Member] | Orthopaedic Facility Optimization [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance	0
Restructuring charges	426
Write-offs	0
Cash payments	(426)
Restructuring Reserve, Ending Balance	0
Other Restructuring [Member] | Legacy Lake Region Medical Consolidation [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance	596
Restructuring charges	1,802
Write-offs	0
Cash payments	(1,942)
Restructuring Reserve, Ending Balance	456
Other Restructuring [Member] | Investments in Capacity and Capabilities [Member]
Restructuring Reserve [Roll Forward]
Restructuring Reserve, Beginning Balance	1,595
Restructuring charges	12,034
Write-offs	0
Cash payments	(13,629)
Restructuring Reserve, Ending Balance	$ 0

Other Operating Expenses, Net63

Other Operating Expenses, Net (Narrative) (Details) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016USD ($)	Oct. 02, 2015USD ($)	Sep. 30, 2016USD ($)facilitybuilding	Oct. 02, 2015USD ($)
Restructuring Cost and Reserve [Line Items]
Other Cost and Expense, Operating	$ 13,370	$ 13,844	$ 50,004	$ 29,449
Spinoff [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Cost Incurred to Date	10,400		10,400
Professional Fees	20	3,100	4,400	4,600
Investments in Capacity and Capabilities [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring And Related Activities Capital Expenditures Incurred To Date	23,200		23,200
Restructuring and Related Cost, Cost Incurred to Date	45,800		45,800
Other Cost and Expense, Operating	4,542	5,116	13,821	17,854
Investments in Capacity and Capabilities [Member] | Minimum [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring And Related Activities Expected Capital Expenditures	25,000		25,000
Restructuring and Related Cost, Expected Cost	46,000		46,000
Investments in Capacity and Capabilities [Member] | Minimum [Member] | Severance And Retention [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	5,000		5,000
Investments in Capacity and Capabilities [Member] | Minimum [Member] | Accelerated Depreciation And Asset Write Offs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	2,000		2,000
Investments in Capacity and Capabilities [Member] | Minimum [Member] | Other Restructuring [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	39,000		39,000
Investments in Capacity and Capabilities [Member] | Maximum [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring And Related Activities Expected Capital Expenditures	28,000		28,000
Restructuring and Related Cost, Expected Cost	52,000		52,000
Investments in Capacity and Capabilities [Member] | Maximum [Member] | Severance And Retention [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	6,000		6,000
Investments in Capacity and Capabilities [Member] | Maximum [Member] | Accelerated Depreciation And Asset Write Offs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	3,000		3,000
Investments in Capacity and Capabilities [Member] | Maximum [Member] | Other Restructuring [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	43,000		43,000
Orthopaedic Facility Optimization [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring And Related Activities Capital Expenditures Incurred To Date	30,000		$ 30,000
Restructuring and Related Costs, Facility Consolidations | building			2
Restructuring and Related Cost, Cost Incurred to Date	44,500		$ 44,500
Other Cost and Expense, Operating	329	357	628	1,348
Orthopaedic Facility Optimization [Member] | Severance And Retention [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	11,000		11,000
Orthopaedic Facility Optimization [Member] | Accelerated Depreciation And Asset Write Offs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	13,000		13,000
Orthopaedic Facility Optimization [Member] | Minimum [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring And Related Activities Expected Capital Expenditures	31,000		31,000
Restructuring and Related Cost, Expected Cost	45,000		45,000
Orthopaedic Facility Optimization [Member] | Minimum [Member] | Other Restructuring [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	21,000		21,000
Orthopaedic Facility Optimization [Member] | Maximum [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring And Related Activities Expected Capital Expenditures	35,000		35,000
Restructuring and Related Cost, Expected Cost	48,000		48,000
Orthopaedic Facility Optimization [Member] | Maximum [Member] | Other Restructuring [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	24,000		24,000
Legacy Lake Region Medical Consolidation [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring And Related Activities Capital Expenditures Incurred To Date	1,700		$ 1,700
Restructuring and Related Costs, Facility Consolidations | facility			2
Restructuring and Related Cost, Cost Incurred to Date	9,300		$ 9,300
Restructuring and Related Costs, Number of Facilities After Consolidation | facility			1
Other Cost and Expense, Operating	2,908	0	$ 7,355	0
Legacy Lake Region Medical Consolidation [Member] | Minimum [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring And Related Activities Expected Capital Expenditures	5,000		5,000
Restructuring and Related Cost, Expected Cost	20,000		20,000
Legacy Lake Region Medical Consolidation [Member] | Minimum [Member] | Accelerated Depreciation And Asset Write Offs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	1,000		1,000
Legacy Lake Region Medical Consolidation [Member] | Minimum [Member] | Other Restructuring [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	11,000		11,000
Legacy Lake Region Medical Consolidation [Member] | Minimum [Member] | Employee Severance [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	8,000		8,000
Legacy Lake Region Medical Consolidation [Member] | Maximum [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring And Related Activities Expected Capital Expenditures	6,000		6,000
Restructuring and Related Cost, Expected Cost	25,000		25,000
Legacy Lake Region Medical Consolidation [Member] | Maximum [Member] | Accelerated Depreciation And Asset Write Offs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	2,000		2,000
Legacy Lake Region Medical Consolidation [Member] | Maximum [Member] | Other Restructuring [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	13,000		13,000
Legacy Lake Region Medical Consolidation [Member] | Maximum [Member] | Employee Severance [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	10,000		10,000
Acquisition And Integration Costs [Member]
Restructuring Cost and Reserve [Line Items]
Other Cost and Expense, Operating	5,319	5,202	23,143	5,366
Asset Dispositions Severance And Other [Member]
Restructuring Cost and Reserve [Line Items]
Other Cost and Expense, Operating	272	3,169	5,057	$ 4,881
Lake Region Medical [Member] | Acquisition And Integration Costs [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Cost Incurred to Date	31,700		31,700
Acquisition related transaction costs	200	$ 5,100	4,200
Business Combination, Integration Related Costs	5,200		18,900
Business Combination, Integration Related Costs Accrued	5,800		5,800
Lake Region Medical [Member] | Acquisition And Integration Costs [Member] | Minimum [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	40,000		40,000
Restructuring And Related Costs, Expected Capital Investment	20,000		20,000
Lake Region Medical [Member] | Acquisition And Integration Costs [Member] | Maximum [Member]
Restructuring Cost and Reserve [Line Items]
Restructuring and Related Cost, Expected Cost	50,000		50,000
Restructuring And Related Costs, Expected Capital Investment	$ 25,000		$ 25,000

Income Taxes (Narrative) (Detai

Income Taxes (Narrative) (Details) - USD ($) $ in Millions	3 Months Ended	9 Months Ended		12 Months Ended
	Sep. 30, 2016	Sep. 30, 2016	Oct. 02, 2015	Dec. 30, 2016
Schedule Of Income Taxes [Line Items]
Effective income tax rate		41.30%	20.40%
Discrete tax charges related to non-deductible Lake Region Medical and Spin-off	$ 2.9	$ 1.6
Unrecognized Tax Benefits	9.8	9.8
Significant Change in Unrecognized Tax Benefits is Reasonably Possible, Amount of Unrecorded Benefit	0.1	0.1
Unrecognized Tax Benefits that Would Impact Effective Tax Rate	$ 9	$ 9
Scenario, Forecast [Member]
Schedule Of Income Taxes [Line Items]
Effective income tax rate				(30.00%)

Commitments and Contingencies65

Commitments and Contingencies (Schedule of Product Warranty Liability) (Details) $ in Thousands	9 Months Ended
	Sep. 30, 2016USD ($)
Movement in Standard Product Warranty Accrual [Roll Forward]
At January 1, 2016	$ 3,316
Additions to warranty reserve	1,568
Warranty claims settled	(2,351)
At September 30, 2016	$ 2,533

Commitments and Contingencies66

Commitments and Contingencies (Foreign Currency Contracts) (Details) $ in Thousands	3 Months Ended			9 Months Ended
	Sep. 30, 2016USD ($)	Jan. 01, 2016USD ($)	Oct. 02, 2015USD ($)	Sep. 30, 2016USD ($)	Oct. 02, 2015USD ($)
Foreign Currency Cash Flow Hedges [Abstract]
Addition in cost of sales	$ 929		$ 562	$ 2,316	$ 1,226
Ineffective portion of change in fair value	$ 0		$ 0	0	$ 0
Foreign Currency Cash Flow Hedge [Line Items]
Foreign Currency Contracts Description	From time to time, the Company enters into forward contracts to purchase Mexican pesos in order to hedge the risk of peso-denominated payments associated with operations at its facilities in Mexico
Payments for termination of foreign currency contract		$ 2,400
Foreign currency cash flow hedge gain (loss) to be reclassified	$ 1,700			1,700
Terminated FX Contract [Member]
Foreign Currency Cash Flow Hedge [Line Items]
Foreign currency cash flow hedge gain (loss) to be reclassified	(300)			(300)
FX Contract 1 [Member]
Foreign Currency Cash Flow Hedge [Line Items]
Aggregate Notional Amount	$ 4,120			$ 4,120
Start Date				Jan. 1, 2016
End Date				Dec. 31, 2016
$/Peso	0.0584			0.0584
FX Contract 2 [Member]
Foreign Currency Cash Flow Hedge [Line Items]
Aggregate Notional Amount	$ 2,795			$ 2,795
Start Date				Apr. 1, 2016
End Date				Dec. 31, 2016
$/Peso	0.0565			0.0565
FX Contract 3 [Member]
Foreign Currency Cash Flow Hedge [Line Items]
Aggregate Notional Amount	$ 18,490			$ 18,490
Start Date				Jan. 1, 2017
End Date				Sep. 1, 2017
$/Peso	0.0514			0.0514
FX Contract 4 [Member]
Foreign Currency Cash Flow Hedge [Line Items]
Aggregate Notional Amount	$ 6,164			$ 6,164
Start Date				Oct. 1, 2017
End Date				Dec. 1, 2017
$/Peso	0.0514			0.0514
Accrued Expenses [Member] | FX Contract 1 [Member]
Foreign Currency Cash Flow Hedge [Line Items]
Fair Value	$ (506)			$ (506)
Accrued Expenses [Member] | FX Contract 2 [Member]
Foreign Currency Cash Flow Hedge [Line Items]
Fair Value	(258)			(258)
Accrued Expenses [Member] | FX Contract 3 [Member]
Foreign Currency Cash Flow Hedge [Line Items]
Fair Value	(415)			(415)
Other Long-Term Liabilities [Member] | FX Contract 4 [Member]
Foreign Currency Cash Flow Hedge [Line Items]
Fair Value	$ (268)			$ (268)

Commitments and Contingencies67

Commitments and Contingencies (Narrative) (Details)	Jan. 26, 2016USD ($)patent	Sep. 30, 2016USD ($)	Jan. 01, 2016USD ($)	Sep. 30, 2016USD ($)
Gain Contingencies [Line Items]
Gain (Loss) Related to Litigation Settlement				$ 0
Product Warranty Description				The Company generally warrants that its products will meet customer specifications and will be free from defects in materials and workmanship.
Foreign Currency Contracts Description		From time to time, the Company enters into forward contracts to purchase Mexican pesos in order to hedge the risk of peso-denominated payments associated with operations at its facilities in Mexico
Payments for termination of foreign currency contract			$ 2,400,000
Self-insurance reserves		$ 6,700,000	7,900,000	$ 6,700,000
Positive Outcome of Litigation [Member]
Gain Contingencies [Line Items]
Gain Contingency, Patents Found Infringed upon, Number | patent	2
Litigation Settlement, Amount	$ 37,500,000
Other Noncurrent Liabilities [Member]
Gain Contingencies [Line Items]
Accrual for Environmental Loss Contingencies		$ 1,100,000	$ 1,100,000	$ 1,100,000

Earnings (Loss) Per Share (EP68

Earnings (Loss) Per Share (EPS) (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Oct. 02, 2015	Sep. 30, 2016	Oct. 02, 2015
Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]
Net income (loss)	$ 11,458	$ 22	$ (1,972)	$ 17,313
Weighted Average Number of Shares Outstanding Reconciliation [Abstract]
Basic	30,782,000	25,536,000	30,756,000	25,424,000
Effect of dilutive securities stock options, restricted stock and restricted stock units	371,000	905,000	0	948,000
Denominator for diluted EPS	31,153,000	26,441,000	30,756,000	26,372,000
Basic EPS (in dollars per share)	$ 0.37	$ 0	$ (0.06)	$ 0.68
Diluted EPS (in dollars per share)	$ 0.37	$ 0	$ (0.06)	$ 0.66
Anitdilutive Securities Excluded From Earnings Per Share [Abstract]
Time-vested stock options, restricted stock and restricted stock units	629,000	260,000	1,862,000	268,000
Performance-vested stock options and restricted stock units	373,000	11,000	417,000	10,000

Accumulated Other Comprehensi69

Accumulated Other Comprehensive Income (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Oct. 02, 2015	Sep. 30, 2016	Oct. 02, 2015
Defined Benefit Plan Liability
Defined Benefit Plan Liability, Beginning	$ (1,179)	$ (1,181)	$ (1,179)	$ (1,181)
Defined Benefit Plan Liability, Ending	(1,179)	(1,181)	(1,179)	(1,181)
Cash Flow Hedges
Cash Flow Hedges, Beginning	(3,746)	(3,619)	(2,392)	(2,558)
Unrealized loss on cash flow hedges	(101)	(1,670)	(2,842)	(3,857)
Realized gain loss on foreign currency hedges - before tax	929	562	2,316	1,226
Realized gain loss on interest rate swaps - before tax	50	2,169	50	2,631
Cash Flow Hedges, End	(2,868)	(2,558)	(2,868)	(2,558)
Foreign Currency Translation Adjustment
Foreign Currency Translation Adjustment, Beginning	12,668	9,839	3,609	11,450
Net foreign currency translation gain (loss)	3,191	144	12,250	(1,467)
Foreign Currency Translation Adjustment, End	15,859	9,983	15,859	9,983
Total Pre-Tax Amount
Total Pre-Tax Amount, Beginning	7,743	5,039	38	7,711
Unrealized loss on cash flow hedges	(101)	(1,670)	(2,842)	(3,857)
Realized gain loss on foreign currency hedges - before tax	929	562	2,316	1,226
Realized gain loss on interest rate swaps - before tax	50	2,169	50	2,631
Net foreign currency translation gain (loss)	3,191	144	12,250	(1,467)
Total Pre-Tax Amount, End	11,812	6,244	11,812	6,244
Tax
Tax, Beginning	1,806	1,784	1,332	1,412
Unrealized gain (loss) on cash flow hedges	35	584	995	1,350
Realized gain loss on foreign currency contracts - tax	(324)	(197)	(810)	(429)
Realized gain loss on interest rate swap hedges - tax	(18)	(759)	(18)	(921)
Net foreign currency translation gain (loss)	0	0	0	0
Tax, End	1,499	1,412	1,499	1,412
Net-of-Tax Amount
Total Net-of-Tax Amount, Beginning	9,549	6,823	1,370	9,123
Unrealized gain (loss) on cash flow hedges, net of tax	(66)	(1,086)	(1,847)	(2,507)
Realized gain loss on foreign currency hedges, net of tax	605	365	1,506	797
Realized gain loss on interest rate swap hedges, net of tax	32	1,410	32	1,710
Foreign currency translation gain (loss)	3,191	144	12,250	(1,467)
Total Net-of-Tax Amount, End	$ 13,311	$ 7,656	$ 13,311	$ 7,656

Fair Value Measurements (Schedu

Fair Value Measurements (Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis) (Details) - Fair Value, Measurements, Recurring [Member]	Sep. 30, 2016USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency contracts liabilities	$ 1,447,000
Interest Rate Swap [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest rate swap assets	75,000
Interest rate swap liabilities	974,000
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency contracts liabilities	0
Fair Value, Inputs, Level 1 [Member] | Interest Rate Swap [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest rate swap assets	0
Interest rate swap liabilities	0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency contracts liabilities	1,447,000
Fair Value, Inputs, Level 2 [Member] | Interest Rate Swap [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest rate swap assets	75,000
Interest rate swap liabilities	974,000
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency contracts liabilities	0
Fair Value, Inputs, Level 3 [Member] | Interest Rate Swap [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Interest rate swap assets	0
Interest rate swap liabilities	$ 0

Fair Value Measurements (Narrat

Fair Value Measurements (Narrative) (Details) - USD ($)	3 Months Ended	9 Months Ended
	Oct. 02, 2015	Sep. 30, 2016	Oct. 02, 2015	Jan. 01, 2016
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Foreign currency cash flow hedge gain (loss) to be reclassified		$ 1,700,000
Long-lived asset impairment loss		1,000,000	$ 0
Goodwill impairment loss		0	0
Indefinite-lived intangible assets (excluding goodwill) impairment loss		0	0
Cost-method investment impairment loss		0	0
Equity method investments, carrying value		24,400,000		$ 20,600,000
Income from equity method investment	$ 4,600,000
Equity method investment cash distribution	$ 3,400,000
Fair Value, Inputs, Level 2 [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Gain on cost method and equity method investments		$ 900,000	$ 5,100,000
Chinese Venture Capital Fund [Member]
Fair Value Inputs, Liabilities, Quantitative Information [Line Items]
Equity method investment ownership (percent)		7.00%

Business Segment, Geographic 72

Business Segment, Geographic And Concentration Risk Information (Reconciliation of Revenue from Segments to Consolidated) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Oct. 02, 2015	Sep. 30, 2016	Oct. 02, 2015
Segment Reporting, Revenue Reconciling Item [Line Items]
Sales Revenue, Net	$ 346,567	$ 146,637	$ 1,027,187	$ 482,847
Interproduct-Line Eliminations [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Sales Revenue, Net	(1,547)	0	(4,631)	0
Intersegment Eliminations [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Sales Revenue, Net	(512)	(160)	(1,995)	(1,501)
Greatbatch Medical [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenue From Intersegment Sales	200		500
Greatbatch Medical [Member] | Operating Segments [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Sales Revenue, Net	140,458	144,021	413,231	473,784
QiG [Member] | Operating Segments [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Sales Revenue, Net	2,708	2,776	8,829	10,564
Lake Region Medical [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Revenue From Intersegment Sales	300		1,300
Lake Region Medical [Member] | Operating Segments [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Sales Revenue, Net	203,913	0	607,122	0
Cardio And Vascular [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Sales Revenue, Net	148,273	14,107	426,142	37,370
Cardiac Neuromodulation [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Sales Revenue, Net	95,781	75,577	284,479	248,450
Advanced Surgical, Orthopedics, and Portable Medical [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Sales Revenue, Net	95,190	44,976	290,836	150,795
Electrochem [Member]
Segment Reporting, Revenue Reconciling Item [Line Items]
Sales Revenue, Net	$ 8,870	$ 11,977	$ 30,361	$ 46,232

Business Segment, Geographic 73

Business Segment, Geographic And Concentration Risk Information (Reconciliation of Operating Profit (Loss) from Segments to Consolidated) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Oct. 02, 2015	Sep. 30, 2016	Oct. 02, 2015
Segment Reporting Information [Line Items]
Operating income	$ 36,862	$ 1,195	$ 77,265	$ 23,618
Unallocated expenses, net	(28,145)	(1,189)	(80,623)	(1,857)
Income (loss) before provision (benefit) for income taxes	8,717	6	(3,358)	21,761
Operating Segments [Member]
Segment Reporting Information [Line Items]
Operating income	46,454	13,832	114,679	52,047
Operating Segments [Member] | Greatbatch Medical [Member]
Segment Reporting Information [Line Items]
Operating income	15,986	21,512	41,565	72,179
Operating Segments [Member] | QiG [Member]
Segment Reporting Information [Line Items]
Operating income	562	(7,680)	(5,347)	(20,132)
Operating Segments [Member] | Lake Region Medical [Member]
Segment Reporting Information [Line Items]
Operating income	29,906	0	78,461	0
Segment Reconciling Items [Member]
Segment Reporting Information [Line Items]
Operating income	$ (9,592)	$ (12,637)	$ (37,414)	$ (28,429)

Business Segment, Geographic 74

Business Segment, Geographic and Concentration Risk Information Business Segment, Geographic and Concentration Risk Information (Schedule of Revenue From External Customers Attributed to Foreign Countries By Geographic Area) (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Oct. 02, 2015	Sep. 30, 2016	Oct. 02, 2015
Revenue, Major Customer [Line Items]
Sales Revenue, Net	$ 346,567	$ 146,637	$ 1,027,187	$ 482,847
UNITED STATES
Revenue, Major Customer [Line Items]
Sales Revenue, Net	206,663	71,545	612,876	217,102
PUERTO RICO
Revenue, Major Customer [Line Items]
Sales Revenue, Net	41,745	26,816	120,217	98,247
BELGIUM
Revenue, Major Customer [Line Items]
Sales Revenue, Net	14,256	12,305	52,913	45,690
Rest Of World [Member]
Revenue, Major Customer [Line Items]
Sales Revenue, Net	$ 83,903	$ 35,971	$ 241,181	$ 121,808

Business Segment, Geographic 75

Business Segment, Geographic and Concentration Risk Information (Schedule of Revenue By Major Customers By Reporting Segments) (Details) - customer	3 Months Ended		9 Months Ended
	Sep. 30, 2016	Oct. 02, 2015	Sep. 30, 2016	Oct. 02, 2015
Revenue, Major Customer [Line Items]
Revenue Major Customer Percent	47.00%	46.00%	46.00%	50.00%
Customer A [Member]
Revenue, Major Customer [Line Items]
Revenue Major Customer Percent	18.00%	17.00%	18.00%	20.00%
Customer B [Member]
Revenue, Major Customer [Line Items]
Revenue Major Customer Percent	18.00%	19.00%	16.00%	18.00%
Customer C [Member]
Revenue, Major Customer [Line Items]
Revenue Major Customer Percent	11.00%	10.00%	12.00%	12.00%
Sales Revenue, Net [Member] | Customer Concentration Risk [Member]
Revenue, Major Customer [Line Items]
Concentration risk, number of customers			3

Business Segment, Geographic 76

Business Segment, Geographic And Concentration Risk Information (Schedule of Long-Lived Assets By Geographical Areas) (Details) - USD ($) $ in Thousands	Sep. 30, 2016	Jan. 01, 2016
Segment Reporting, Asset Reconciling Item [Line Items]
Property, plant and equipment, net	$ 381,671	$ 379,492
UNITED STATES
Segment Reporting, Asset Reconciling Item [Line Items]
Property, plant and equipment, net	263,347	264,556
Rest Of World [Member]
Segment Reporting, Asset Reconciling Item [Line Items]
Property, plant and equipment, net	$ 118,324	$ 114,936

Business Segment, Geographic 77

Business Segment, Geographic and Concentration Risk Information (Narrative) (Details)	9 Months Ended
	Sep. 30, 2016Segment
Segment Reporting Information [Line Items]
Number of Reportable Segments	3